


















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 





























A thesis submitted for the degree of Doctor of 








Institute for Infectious Disease and Molecular Medicine 
Department of Immunology 























I, Cristal Huysamen, hereby declare that the work on which this thesis is based, is my 
original work (except where acknowledgments indicate otherwise) and that neither the 
whole work or any part thereof has been, is being or is to be submitted for another 
degree in this or any other University. 
 
I empower the University of Cape Town to reproduce for the purpose of research 













































This thesis is dedicated to my parents 







































Table of contents   Page
   
Declaration  ii 
Dedication  iii 
Acknowledgements  vii 
Abstract  viii 
Abbreviations  ix 
Symbols  xiii 
List of Solutions  xiv 
List of Tables  xvi 
List of Figures  xvi 
Appendix for publications  xviii 
 
Chapter 1: Introduction  
   
1.1 Cell surface receptors 1 
1.2 Receptor families and superfamilies  2 
1.3 C-type lectins and lectin-like receptors 4 
1.4 The function of CTLRs in the immune system 7 
1.4.1        The role of CTLRs in leukocyte trafficking 9 
1.4.2        Antigen presenting cell T-cell interactions 10 
1.4.3        Antigen uptake by CTLRs 10 
1.4.4        CTLRs and pathogen recognition 11 
1.4.5        The role of CTLR signaling 12 
1.5 The Natural-Killer gene complex encoding lectin-like NK-receptors 15 
1.6 General features of the group V C-type lectin receptors 18 
1.7 Dectin-1 cluster of C-type lectins 20 
1.7.1        Dectin-1 (CLEC7A) 22 
1.7.2        LOX-1 (CLEC8A, OLR1) 27 
1.7.3        CLEC-1 (CLEC1A) 30 
1.7.4        CLEC-2 (CLEC1B) 31 
1.7.5        MICL (CLEC12A) 32 
1.7.6        CLEC12B (Macrophage antigen H) 34 
1.8 CLEC9A 35 
1.8.1       Aims of this thesis 35 
   
Chapter 2: Materials and methods  
  
2.1 Cells 36 
2.1.1        Cell lines used 36 
2.1.2        General cell culture  36 
2.1.3        Isolation of culture of human monocyte derived macrophages/DCs 38 
2.1.4        Isolation of peripheral blood leukocytes 39 
2.2 General methods 39 











2.2.2       Agarose gel electrophoresis 40 
2.2.3       Purification of DNA from agarose gels 40 
2.2.4       Plasmid digestion 41 
2.2.5       Plasmid dephosphorylation 41 
2.2.6       Phenol/chloroform extraction of DNA 41 
2.2.7       Ligation of plasmid vectors and insert DNA 42 
2.2.8       Butanol precipitation 42 
2.2.9       Transformation and colony selection 43 
2.2.10       Colony PCR 43 
2.2.11       Plasmid minipreps 44 
2.2.12       Isolation of genomic DNA 44 
2.2.13       Isolation of RNA and reverse-transcription 45 
2.2.14       Formaldehyde gel electrophoresis gel 46 
2.2.15       SDS-Polyacrylamde gel electrophoresis (PAGE) 46 
2.2.16       Antibody purification and biotinylation 47 
2.2.17       Purification of polyclonal antibody 47 
2.3 Transfection/transduction of cell lines and flow cytometry 49 
2.3.1       Transient transfection using Fugene6 49 
2.3.2       Retrovirus production 49 
2.3.3       Retroviral transduction and selection of cell lines 50 
2.3.4       Flow cytometry 50 
2.4 Techniques specific to this study 51 
2.4.1       Computer tools 51 
2.4.2       Generation of cell lines and transduced cell lines 52 
2.4.3       The generation and testing of monoclonal antibodies (mAb) 54 
2.4.4       Western blotting and deglycosylation 56 
2.4.5       Cell sorting 57 
2.4.6       Immunostaining of NIH3T3 cells 58 
2.4.7       Endocytosis assays 58 
2.4.8       Phagocytosis assays 60 
2.4.9       Zymosan binding and cytokine assays 61 
2.4.10       Immunoprecipitations 62 
2.4.11       Reporter cells 62 
2.4.12       Endogenous and exogenous ligand screen 63 
2.4.13       Immunohistochemistry 64 
   
Chapter 3: Identification and In silico analysis  
   
3.1 Identification of CLEC9A   65 
3.2 Results 66 
3.2.1       Sequence analysis and genomic structure of CLEC9A 66 
3.2.2       Homologies with other species and known C-type lectins 71 
3.3 Discussion 75 
   
Chapter 4: Characterization of CLEC9A expression  
  
4.1 Introduction 78 
4.2 Results 79 











4.2.2       CLEC9A is expressed at the cell surface as a glycosylated dimer 82 
4.2.3       Expression of hCLEC9A on primary cells 86 
4.2.4       The generation and testing of anti-CLEC9A antibody 87 
4.2.5       Distribution of CLEC9A within peripheral blood 93 
4.2.6       hCLEC9A expression on in vitro cultured macrophages and  
      DCs, and tissues 
97 
4.3 Discussion 99 
   
Chapter 5: Functional characterization of CLEC9A  
   
5.1 Introduction 103 
5.2 Results 105 
5.2.1       Endocytic ability of hLEC9A 105 
5.2.2       Phagocytic function of hCLEC9A 108 
5.2.3       hCLEC9A is an activation receptor 112 
5.2.3.1       Cytokine production by CLEC9A 114 
5.2.3.2       The kinases associated with the ITAM-like motif of hCLEC9A 114 
5.2.4       hCLEC9A is Syk dependent for activation 116 
5.3 Discussion 118 
   
Chapter 6: Ligand screen for mCLEC9A  
   
6.1 Introduction 122 
6.2 Results 122 
6.2.1       Ligand screen of mCLEC9A using reporter cells 122 
6.2.2       Screening tissues with an Fc-mCLEC9A soluble protein 126 
6.2.3       Immunohistochemistry of tissues stained with Fc-mCLEC9A 126 
6.2.4       Screening various heat-killed pathogens as possible exogenous ligands 130 
6.2.5       Screening soluble Fc-proteins as possible ligands 130 
6.3 Discussion 132 
   
Chapter 7: General discussion  
   
7.1 Review of aims of the project 137 
7.2 Summary of key findings 137 
7.2.1      CLEC9A is a novel human CTLR with an ITAM-like motif 137 
7.2.2        hCLEC9A is predominantly expressed as a single transcript on blood DC  
       and a subset of monocytes 
138 
7.2.3       hCLEC9A protein is expressed at the cell surface as a dimer and is N- 
      glycosylated 
139 
7.2.4       hCLEC9A can associate and signal via Syk kinase and is able to transmit  
      activatory signals via its ITAM  
139 
7.2.5       hCLEC9A is an endocytic receptor 140 
7.2.6       hCLEC9A is not a true phagocytic receptor 140 
7.3 Future directions  141 
7.3.1       True physiological function 141 














First and foremost, I thank God for giving me the strength, patience and persistence to 
see me through this study. 
 
I would like to express my sincere gratitude to the various people who have supported 
and guided me over the years and contributed to the completion of this thesis. I 
especially want to thank: 
 
Prof. Gordon Brown, my supervisor, who has guided and encouraged me throughout 
my research. Thank you for always being available for advice and with the critical 
review of this thesis. Your knowledge in this field has been a true inspiration. It was a 
great honor to be part of your group. 
 
To my colleagues, who became my friends, at the Department of Immunology, thank 
you for your continuous motivation, advice and the coffee breaks when I needed it the 
most. To Janet Willment for all her patience and support while teaching me so many 
of the techniques I know today. To Vicky Tsoni I sincerely express my gratitude for 
her support from the beginning of this journey up until completing my thesis, her 
expert assistance with animal work and the reviewing of this thesis. To Lisa Graham 
and Ann Kerrigan for their friendly and helpful way in which they assisted me when 
the experiments were unsuccessful, double-checking the calculations, reviewing of 
this thesis and socializing outside the laboratory. To Georgia Schafer for her advise 
and reviewing of this thesis. To Kevin Dennehy for his expert advice, experimental 
ideas and always looking for somebody to bring cake for the Friday meetings. To 
Elwira Pyz for her experimental contributions and guidance. To Inês Trinidade for 
helping me collect and analyze figures. To Chris van Eeden and Janice Odgen for 
managing the laboratory and their willingness to help. 
 
To the staff of the UCT animal facility, especially Hiram Arendse, for the friendly and 
helpful way they assisted me and providing an excellent service. 
 
I am grateful to the National Research foundation, Harry Crossley Scholarship, 
Marion Beatrice Waddel Bursary and KW Johnstone Research Scholarship for their 
financial support. 
 
Last but definitely not the least, a special thanks to Kobus van Deventer who 
encouraged me to stay positive and not to give up and stood by me through the tough 






















I describe here the first characterization of CLEC9A, a group V C-type lectin-like 
receptor located in the “Dectin-1 cluster” of related receptors, which are encoded 
within the Natural Killer-gene complex. Expression of human CLEC9A is highly 
restricted in peripheral blood, being detected only on BDCA3+ dendritic cells and on a 
small subset of CD14+CD16- monocytes.  CLEC9A is expressed at the cell surface as 
a glycosylated dimer and can mediate endocytosis, but not phagocytosis. CLEC9A 
possesses a cytoplasmic immunoreceptor-tyrosine based activation-like motif that can 
recruit Syk kinase and we demonstrate, using receptor chimeras, that this receptor can 
induce proinflammatory cytokine production. These data indicate that CLEC9A 
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1.1 Cell surface receptors 
Every host has specialised mechanisms to protect it from invading organisms and disease. 
Both the innate and adaptive immune responses depend upon the activities of leukocytes 
for an effective defense system. Leukocytes identify and eliminate pathogens, either by 
attacking larger pathogens through contact or engulfing and then killing them [1]. In 
order for these cells to execute their immune function they require a wide and flexible, 
yet specific and regulated, repertoire of cell surface receptors. Cell surface receptors are 
involved in leukocyte development, migration, differentiation, proliferation, maturation 
and survival; these receptors are also able to discriminate between host versus foreign 
molecules and eliminate aberrant host cells, such as cells that are transformed or virally 
infected; as well as mediating complex intracellular signaling cascades that coordinate 
various cellular responses. The majority of leukocyte cell surface receptors appear to be 
involved in mediating intracellular signaling responses [2]. 
 
Many cell surface receptors have the ability to recognize more than just one exogenous or 
endogenous ligand, associates with several intracellular molecules and engage in 
interactions with other transmembrane proteins. Leukocytes express a great number of 
different cell surface receptors [3], and the characterization of the function of each 
receptor is a clearly a complex task, but essential for understanding the basic biology of 











1.2  Receptor families and superfamilies 
Cell surface receptors are classified into families or subfamilies based on their function, 
structural domains or conserved amino acid sequences. Family members that share 
structural homology may have related functions, however, it may also include members 
with non-conforming divergent functions. Receptors that are structurally homologous are 
usually derived from a common ancestor and are likely to have been generated by genetic 
changes such as exon shuffling, gene duplication and gene fusion [4]. 
 
The major structurally defined superfamily of cell surface receptors is the 
immunoglobulin superfamily (IgSF) commonly associated with roles in the immune 
system [5]. This family extends to the leukocyte cell surface where the immunoglobin 
(Ig) domain is found in approximately a third of known proteins and is involved in the 
recognition, binding or adhesion processes of cells [2]. There is a great number of other 
leukocyte cell surface protein families defined by their structural domains including 
integrins, complement control proteins, C-type lectins, G-protein coupled receptors and 
cytokine receptor domains. Some of these proteins contain more than one structurally 
defined domain and are capable of activating intracellular signaling cascades to regulate 
numerous cellular functions, for example phagocytosis, cytokine production and the 
synthesis of reactive oxygen species (ROS). 
 
The pattern recognition receptors (PRRs) represent one of the functionally defined group 
of receptors, important to the innate immune system [6]. PRRs recognize 











which are characterized as being critical for pathogen survival, unrelated to host 
molecules and are often conserved amongst several mammalian species. The PRR 
concept explains how primitive organisms such as Drosophila melanogaster, which have 
no adaptive immune response, have the ability to combat a wide variety of pathogens 
with a relatively small repertoire of germ-line encoded immune receptors. PRRs are most 
notably represented by Toll-like receptors (TLRs), named after the fruit-fly receptor Toll, 
which was first discovered because of its important role in early fly development and 
later recognized as a major role player in innate immunity in adult flies [7]. Other PRRs 
include members of the C-type lectin superfamily, which recognize conserved pathogen-
associated carbohydrates. 
 
The mammalian genomes encode a variety of carbohydrate-binding molecules, which are 
collectively referred to as lectins [8]. This group of molecules is another superfamily of 
cellular proteins that can be defined by their structural domain and their intracellular 
signaling abilities. These proteins serve many different biological functions ranging from 
cell-cell adhesion, plasma glycoprotein turnover and innate pathogen recognition. Lectins 
play important roles i  the immune system by recognizing carbohydrates at cell surfaces, 
on circulating proteins as well as those present on pathogens [9]. These circulating lectins 
include various soluble or transmembrane proteins. The cytoplasmic tails of most of these 
lectins are diverse and contain several conserved signaling motifs that are important for 
antigen uptake, intracellular signaling and the production of proinflammatory cytokines. 












1.3 C-type lectins and lectin-like receptors 
About 6% of leukocyte receptor proteins consist of C-type lectin receptors (CTLRs), 
which are involved in a variety of cellular responses [11]. C-type lectins contain a 
characteristic structural motif called the C-type lectin-like domain (CTLD), derived from 
six conserved cysteine residues that form three intra-chain disulfide bonds, which 
stabilizes the CTLD fold [12, 13].  
 
This domain is a popular evolutionary framework for generating new functions and is 
found in various structural and functional contexts [14]. This family of proteins shows 
both evolutionary flexibility and conservation. For example, genomic studies have shown 
that there are virtually no structural similarities between the CTLD of Caenorhabditis 
elegans and the CTLD of Drosophila melanogaster [4], whereas relatively few 
modifications occurred within the vertebrate lineage during evolution from fish to 
mammals [15]. The only common feature between Drosophila melanogaster and 
Caenorhabditis elegans is the domain architecture consisting simply of an isolated CTLD 
[4, 16]. 
 
The CTLD was originally identified as a protein fold in the carbohydrate-recognition 
domain (CRD) of mannose binding lectin but since then it has been found in over 1,000 
proteins [14]. In later studies the CTLD has been shown to specifically bind proteins [17], 
lipids [18], and inorganic compounds (only shown for invertebrates) [19-22]. In some 
cases the domain can bind both protein and sugar [23-25]. CTLD containing receptors 











groups or lectin subfamilies (Figure 1.1) based on the configuration of their CTLD(s) and 
the context amongst any other defined domains [14, 26]. The largest family of lectins are 
the ‘classical’ C-type lectins, and can bind carbohydrates in a Ca2+-dependent manner [8]. 
The molecular mechanism of Ca2+-dependent carbohydrate binding is conserved in all the 
family members studied up to date; the characteristic motifs ‘EPN’ and ‘WND’ form the 
core amino acids involved in this binding site. These motifs can be identified by sequence 
alignment and are indicative of the binding specificity (mannose vs. galactose) [14]. This 
observation provided a popular approach to predict whether the CTLD of an unknown 
function is likely to bind sugar (containing ‘EPN’ and ‘WNP’) or preferentially bind 
mannose- or galactose-type ligands (‘EPN’ vs. ‘OPD’ present) [14]. However, this 
approach is limited for the functional characterization of newly identified receptors, as its 
development was based on the comparison of a limited set of well-characterized domains 
and the number of uncharacterized sequences is quickly growing, including the 
evolutionary distance between the characterized and recently identified sequences. 
 
The ‘non-classical’ C-type lectin receptors, also known as C-type lectin-like receptors, 
share structural homology with their classical counterparts, but lack the conserved 
residues in their CTLD involved in Ca2+-binding [27]. These receptors have evolved to 
recognize non-carbohydrate ligands, however some may be able to recognize 
carbohydrates via alternative mechanisms [28-30]. All proteins containing a CTLD(s), 
including classical and non-classical will be collectively referred to here as ‘C-type lectin 
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WSC domain Collagen domain 
Fig.1.1 Domain architecture of vertebrate C-type lectin domains (CTLDs) from 
different groups. The C-type lectin family is separated into 17 groups based on their 
domain architecture. Group numbers are indicated next to the domain charts. I –lecticans, II 
– the ASGR group, III – collectins, IV – selectins, V – NK receptors, VI – the macrophage 
mannose receptor group, VII – REG proteins, VIII – the chondrolectin group, IX – the 
tetranectin group, X – polycystin 1, XI – attractin, XII – EMBP, XIII – DGCR2, XIV – the 
thrombomodulin group, XV – Bimlec, XVI –SEEC, XVII CBCP. Adapted from Zelensky and 
Gready (FEBS Journal 2005) 











It is possible that the members of each of the 17 groups have evolved from one original 
CLTR, since the sequence of each CTLD is most similar to those within the same group 
[26]. The natural ligand(s) for the majority of individual members are still unknown and 
their biological function is yet to be defined. However, many of the characterized CTLRs 
are involved in various immune system functions, ranging from protective immunity 
through recognizing class I MHC molecules with self-peptides on healthy host cells to 
the killing of tumor or virally infected cells through their specific ligand recognition [31]. 
The functional versatility of this protein superfamily is owed to the diversity of ligands 
recognized by the CTLD. 
 
1.4 The function of CTLRs in the immune system 
Many lectin and lectin-like receptors are expressed on cells of the immune system which 
are important for the cellular functions of these cells [32]. As mentioned previously, this 
large family of receptors have been subdivided according to their structure and function 
(Figure 1.1) [14]. A summary of ome of the major structural and functional relationships 
of the CTLRs and their role in the immune system is outlined in Table 1.1.  A brief 
overview of the some of the important immune functions of selected CTLRs will be 







































Group VI. MMR family
Group V. NK receptors
-ss -
Group II. Type II receptors
Group IV. Selectins
Table 1.1 Overview of the structural and functional relationship of selected 
subfamilies of C-type lectin-like receptors
Group and molecular
structure
C-type lectin Localization Ligand 
specificity
Function Cytoplasmic tail

























DCs, HC, dMØ, aMØ
DCs, Mo, MØ, PMN, B
LC
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KKFV   YQKP
Green sphere, C-type lectin domain; light blue rectangle, fibronectin type II repeat; purple pentogram, ricin 
domain; dark blue pentagon, epidermal growth factor (EGF)-like domain, orange oval, complement regulatory  
domain. Based on the nomenclature from Zelensky and Gready (FEBS Journal 2005). B, B cell; DCAL-1, DC-
associated lectin-1; DMEC, dermal microvascular ECs; EMC, extracellular matrix; HC, Hofbaur cells; LC, 
Langerhans cells; LE, lymphatic endothelium; Mø, d(decidual), a(alveolar) macrophages; Mo, monocytes; NK, 












1.4.1 The role of CTLRs in leukocyte trafficking 
Several CTLRs have been characterized, which are expressed on leukocytes that play a 
role in cell trafficking. [33]. The selectins are of major importance in mediating cell 
adhesion and migration. This family comprises three members, E-, L- and P-selectins, 
and forms the prototype C-type lectin-like receptors [32]. The E- and P-selectin receptors 
are expressed on activated endothelium and play a major role in lymphocyte 
extravasations.  The CTLD of both E- and P-selectin predominantly recognize the Sialyl-
Lewis X (sLEX) carbohydrate, whereas L-selectin can bind CD34 and GlyCAM-1 
(glycosylation-dependent cell adhesion molecule 1), expressed at low levels on 
endothelium.  
 
The macrophage mannose receptor (MMR) can bind to macrophages and B cells through 
its cysteine-rich domain. This receptor has the ability to bind several classes of 
carbohydrates and provides a mechanism for regulating the trafficking and function of 
MMR-bearing cells [34]. MMR is also expressed on dermal microvascular endothelial 
cells (DMECs) and this has been associated with the diverse function of MMR, providing 
the first example of the dual function for a CTLR [32, 35, 36]. 
 
Evidence for a role of C-type lectins in trafficking dendritic cells (DCs) originates from 
the observation that intracellular adhesion molecule 2 (ICAM-2), constitutively expressed 
by endothelium supports tethering and rolling of cells expressing DC-specific ICAM-3 











induced migration of DCs across both resting and activated endothelium in vitro, 
indicating that DC-SIGN is central to this trafficking capacity of DCs [37, 38] 
 
1.4.2 Antigen presenting cell T-cell interactions 
There is increasing evidence that CTLRs are important in the interactions that take place 
during the proliferation of leukocytes after antigen stimulation, which is associated with 
dense antigen-presenting cell (APC)-T-cell clusters. Its been previously shown that DC-
SIGN is highly expressed on DCs, binds ICAM-3 and mediated transient adhesion of 
DCs with T cells [37]. This receptor supports the early antigen-nonspecific contact 
between DCs and T cells, enabling the engagement of T cell receptor by stabilizing the 
DC-T-cell contact zone [37]. 
 
Two other CTLRs, Dectin-1 [39] and DC-associated lectin-1 (DCAL-1) [40] are 
expressed on DCs and macrophages and have been proposed to bind T-cells. Fusion 
proteins of both proteins bind to the surface of T cells and promote their proliferation in 
the presence of anti-CD3 antibodies, suggesting that Dectin-1 and DCAL-1 on DCs bind 
to an undefined endogenous ligand on T cells leading to the delivering of T cell co-
stimulatory signals. 
 
1.4.3 Antigen uptake by CTLRs 
The major function of C-type lectins in microbial recognition is the binding and 
internalization of microbes for direct elimination by macrophages [33]. Some well-











[43, 44] have also been shown to mediate antigen uptake. MMR delivers antigen to the 
early endosomes and recycles back to the surface, whereas DEC-205, BDCA-2 and DC-
SIGN deliver antigens to the late endosomes or lysosomes, where they are degraded. 
These receptors contain various endocytic motifs in their cytoplasmic tail, including the 
tyrosine-based coated pit sequence uptake-motif present in MMR (YxxZ or FxxxxY, 
where X represents any amino acid and Z denotes any amino acid with a hydrophobic 
side chain) and the additional tri-acidic cluster (EEE or DDD) present in DEC-205, 
BDCA-2 and DC-SIGN, important for targeting to proteolytic vacuoles [41]. DC-SIGN 
has a di-leucine motif present in the cytoplasmic tail that is essential for internalization 
[43]. 
 
The ability of CTLRs to mediate endocytosis of ligands is not only important for 
pathogen clearance but at the same time also for the generation of antigenic fragments for 
presentation to T lymphocytes for triggering the adaptive immune system [33]. DEC-205, 
DC-SIGN and BDCA-2 mediate endocytosis and delivers antigen to late endosomal-
lysosomal compartments of APCs and is an efficient means of generating MHC for 
presentation to T-cells [41-43, 45]. Antigen targeting to CTLRs expressed on APCs is 
emerging as a possible strategy for vaccination in humans and mice [46]. 
  
1.4.4 CTLRs and pathogen recognition 
Several CTLRs are capable of recognizing PAMPs and play a role as phagocytic PRRs 
[32]. The role MMR as a PRR is well studied and it has been reported to bind a wide 











tuberculosis [48]. The effect of these interactions to host defense is not fully understood 
although it has been reported that COS-1 cells transfected with MMR mediates 
phagocytosis of yeast and endocytosis of mannosylated BSA [47]. DC-SIGN binds 
numerous pathogens including viruses, fungi, bacteria, protozoa and products from 
metazoan parasites [49]. Dectin-1 and LOX-1 are both PRRs [29, 50], which recognize 
microbial components and can trigger numerous cellular responses including particle 
uptake [51, 52]. 
 
Although some CTLRs have been implicated in the recognition of pathogens, certain 
pathogens target CTLRs to escape immune activation. For example, DC-SIGN has a high 
affinity for the heavily glycosylated envelope glycoproteins of human immunodeficiency 
virus (HIV), however, DC-SIGN mediated uptake of HIV by DCs protect the virus from 
degradation and allow subsequent regurgitation and transmission to T cells [53, 54]. 
Similarly, the internalization of Mycobacterium tuberculosis by MMR aids in the survival 
of this pathogen [55]. These observations suggest that some CTLRs mediated pathogen 
binding and internalization may be misleading and may be indicative of CTLRs 
exploitation by the pathogen rather than pattern recognition leading to immune defense 
[46]. 
 
1.4.5 The role of CTLRs signaling 
The function of Natural-killer C-type lectins (NKCLs) can be divided into activatory or 
inhibitory receptors, depending on the signaling motifs found in their cytoplasmic tails or 











a conserved cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), 
whereas the activatory receptors possess a cytoplasmic immunoreceptor tyrosine-based 
activation motif (ITAM). Some activatory receptors contain a charged residue in their 
transmembrane domain, which can associate with an adaptor molecule (such as DAP10, 
DAP12, CD3ζ or FcRγ-chain) that possesses an ITAM in its cytoplasmic tail. However, it 
is possible that there is neither an obvious adaptor-associating residue nor a signaling 
motif, for example in the case of CLECSF8 [56] (C-type lectin superfamily member 8), 
which can still function endocytically. 
 
The NKCL inhibitory and activatory receptors help regulate and maintain the functional 
balance of leukocytes [57]. Certain members of these inhibitory and activatory receptor 
superfamilies bear one or more cytoplasmic consensus motif (such as ITIMs and ITAMs) 
which have been shown to associate with specific signaling mechanisms, while other 
receptors signal via the adaptor molecules containing such motifs. The ITAM-mediated 
signaling mechanism involves a phophorylation cascade that differs between cell types 
through the use of different kinases within each family. The consensus sequence for 
ITAMs is YxxLx5-12Yx2-3L/I [58]. Upon receptor stimulation the ITAM becomes tyrosine 
phosphorylated by members of the Src family tyrosine kinases, the phosphorylated ITAM 
then binds to Syk family kinases [59]. This tyrosine phosphorylation-based cascade 
continues through a variety of mediators. These ITAM-mediated activatory signals lead 
to a wide range of cellular outcomes, including phagocytosis, proliferation, adhesion and 



















































Fig.1.2 Activation and inhibitory receptors with tyrosine based motifs. Schematic 
representation of an activation receptor containing an ITAM, which becomes phosphoryated 
upon stimulation leading to various cellular responses including phagocytosis and cytokine 
production. The inhibitory receptor possess a ITIM which suppress activatory signals by 











ITIM-mediated inhibition involves dephosphorylation of the activatory cascades (Figure 
1.2). The consensus sequence for ITIMs is I/V/L/SxYxxL/V [60]. The ITIMs are also 
phosphorylated by Src kinases [61] leading to the recruitment of phosphatase enzymes 
such as SH2-domain-containing protein tyrosine phosphatase 1 (SHP-1) and potentially 
other phosphatases, such as SHP-2 and SH2-domain-containing inositol polyphosphate 5’ 
phosphatases (SHIP) [60]. ITIM-mediated inhibitory effects include the inhibition of cell 
maturation, phagocytosis, cytokine production and cellular proliferation [60]. 
 
1.5 The Natural-Killer gene complex encoding lectin-like NK-receptors 
The Natural-Killer gene complex (NKC) encompasses several families of genes encoding 
proteins that share a common structure [62]. The receptors encoded by these genes are 
primarily expressed on NK cells, therefore this genetic region is called the NK gene 
complex [63]. Most molecules encoded by the NKC are receptors that are highly relevant 
to NK-cell and T-cell function. The human NKC is located on the short arm of 
chromosome 12 and encompasse  a region of about 2Mb [64]. In mice the corresponding 
region is located on chromosome 6 [65], which was originally found to contain the NKR-
P1 and Ly49 genes [66]. The NKC contains numerous lectin-like receptor genes, of 
which some are expressed on NK and NK/T cells and function as NK receptors [67]. A 
novel family of genes, expressed on myeloid, DCs and or/ endothelial cells have recently 
become evident, serving as potential regulators of these cells [68].  
 
NK cells are well recognized as playing an important role in the immune system in 











allogeneic cells [31]. The interactions of NK cell receptors with MHC class I and related 
molecules have provided insights into the mechanisms of how the immune system can 
detect and eliminate aberrant host cells, such as cells that are transformed or virally 
infected. Therefore this observation formed the basis for the ‘missing-self’ hypothesis, 
where NK cells survey tissues for the expression of MHC class I molecules [69]. In the 
absence of otherwise ubiquitously expressed MHC class I molecules, the result is the 
release of NK cells from the inhibitory influence of MHC class I molecules leading to 
elimination of the targeted cell (Figure 1.3) [70]. The NK cells respond to the ‘missing 
self’ as a signal of host stress and can be explained as the expression of NK-cell 
inhibitory receptors specific for MHC class I molecules [69]. These inhibitory receptors 
include human killer-cell immunoglobulin-like receptors (KIRs), the rodent Ly49 
receptors and human and rodent CD94-NKG2 molecules [57, 63, 71, 72]. Another 
mechanism of detection is ‘altered-self’ recognition, in which inhibitory C-type lectin-
like NK cell receptors (NKCLRs), e.g. Natural killer cell lectin-like receptor subfamily B 
member 1 D (Nkrp1d) that do not recognize MHC ligands, but other molecules including 
C-type lectin domain family 2 member d (Clec2d) [73], which is often downregulated on 
tumor cells [70].  
 
The cytotoxic function of NK cells is regulated by these inhibitory and activation CTLRs. 
The functional balance of leukocytes other than NK cells are also regulated to a 




































Fig 1.3 The interaction of NK receptors with MHC class I molecules. A) On 
interacting with a normal cell, a natural killer (NK) cell might receive activating signals; 
and because the target cell expresses the appropriate self-MHC class I alleles, the NK 
cell does not lyse the target cell. This is a consequence of inhibitory signals from the 
ligated MHC-binding receptor at the surface of the NK cell. B) If the target cell loses 
expression of MHC class I molecules, owing to viral infection/transformation, the MHC-
binding inhibitory receptor at the surface of the NK cell is not engaged. Thereby, the NK 
cell does not receive inhibitory signals and therefore lyses the target cell. In this case, 
the target cell is perceived by the NK cell to be missing self. C) In the setting of an 
allogeneic transplant, host NK cells interact with donor target cells that express foreign 
MHC class I alleles. In most cases, the foreign, non-self-MHC class I molecules do not 
engage all of the inhibitory receptors at the surface of a host NK cell, leading to lysis of 















1.6 General features of the group V C-type lectin receptors 
The NKC encode the group V CLTRs (Figure 1.1), which have been identified in higher 
vertebrates only [14]. They are usually encoded by six exons and share a common 
structure, forming dimeric type II transmembrane proteins with a single non-calcium 
binding CTLD in their ectodomain, a stalk region of variable length and a cytoplasmic 
tail, which may contain signaling motifs. Although the group V is defined as the “type II 
transmembrane NK cell receptors”, many are not exclusively expressed on NK cells, but 
are also expressed on macrophages and DCs [39, 74]; vascular endothelial cells [75, 76]; 
and on platelets [77]. Thus, these CTLRs expressed on myeloid cells are in contrast to 
their NK cell counterparts, which primarily control cellular activation through the 
recognition of MHC class I and related molecules, therefore the myeloid-expressed 
receptors in group V appear to have more diverse functions [78]. These myeloid-
expressed NKCLs play important roles in both innate and adaptive immunity through 
their ability to modulate myeloid cell functions [78]. 
 
Some of the group V receptors contain cysteine residues within their stalk region, which 
appear to be involved in homo- or hetero-dimerization. The human NKG2A-CD94 and 
NKG2C-CD94 form heterodimers capable of recognizing the non-classical MHC class I 
molecule HLA-E [79]. Multimerisation of these receptors increases ligand affinity and 
specificity [80]. 
 
CTLR gene expression includes: splicing, oligomerization, cell type restriction and 











functional significance of this phenomenon is not well characterized. Many splice 
variants encode lectins that lack the stalk or transmembrane regions, leading to the 
retention of the receptor within the cytoplasm or the generation of soluble forms of the 
receptor, respectively [82, 83].  Alternative splicing may also mediate oligomerisation or 
aid in the flexibility of the CTLD [74, 84]. DCIR has stalked and stalkless isoforms that 
are oppositely regulated by anti- and pro-inflammatory stimuli [85]. 
 
The regulation of CLTRs gene expression has also been well investigated. For example, 
various pro-inflammatory agents such as LPS [86] induce the expression of MINCLE, 
whereas LOX-1 [87] and the MMR [88] expression are upregulated by stimuli including 
anti- and pro-inflammatory cytokines. Soluble CTLRs such as collectins [89] and the 
cleavage of membrane bound CTLRs (e.g. MMR, CD23 and LOX-1) leads to the release 
of the receptor into the extracellular environment, which is another feature of expression 
that can be regulated [90]. These receptors perform various roles after being cleaved, 
such as opsonising pathogens for neutralization [91] or the clearance of host serum 
glycoproteins [34].  
 
In the past decade the number of known activation and inhibitory NKCLs has increased 
considerably and many novel members are still being identified and characterized. The 
role of NK cell receptors appears to be primarily the identification of aberrant, 
transformed or virally infected cells, while the NKCLs appear to have far more divergent 
functions on myeloid cells. These receptors appear to have novel inhibitory and 











physiological characterization in vivo and the identification of the ligand(s) of these 
receptors still remains a major challenge in this field. The future study of these receptors 
will give more insights into myeloid cell biology, and possibly provide alternative targets 
for the modulation of myeloid cell function for the treatment of diseases. 
 
1.7 Dectin-1 cluster of C-type lectins 
The ‘Dectin-1 cluster’ is a CTLR family within the NKC, which are predominantly, but 
not exclusively, expressed by myeloid cells and share common structures: type II 
transmembrane proteins whose extracellular domains have structural features of group V 
C-type lectins, a stalk region of variable length, and a cytoplasmic tail containing various 
signaling motifs. This cluster includes Dectin-1, LOX-1, CLEC-1, CLEC-2, MICL, 
CLEC12B and CLEC9A (Figure 1.4) and most of these receptors appear to have diverse 
ligands, cellular functions and are broadly expressed [78]. The ‘Dectin-1 cluster’ of 
receptors have been shown to recognize a broad range of structurally unrelated ligands, 
however, there are still a few receptors in this cluster that have not yet been functionally 
characterized and the natural ligand(s) are still unknown. The mechanism of the various 
intracellular signaling functions of these specific receptors is not clear in most cases, but 
the functions of the ‘Dectin-1 cluster’ indicates that these molecules may contribute to 
both innate and adaptive immune responses as well as homeostasis. Therefore we will 
focus on describing the receptors of this cluster in detail, as it will develop a better 
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Fig. 1.4 The genomic localization of the “Dectin-1cluster” of C-type lectin 
receptors. Schematic view of the “Dectin-1 cluster” on human chromosome 12p13,  












1.7.1 Dectin-1 (CLEC7A) 
Dectin-1 was originally reported as a cell surface Dendritic cell-specific molecule, from 
which its name ‘dendritic-cell-associated-C-type lectin-1’ was derived [39], but was 
subsequently found in a functional screen of a macrophage derived cDNA expression 
library to be a β-glucan receptor [29]. The expression of Dectin-1 is predominant in 
monocytes, macrophages, neutrophils and microglia, and to a lesser extent in a subset of 
T cells, and, in humans, B cells, mast cells and eosinophils [92-95]. The mouse Dectin-1 
receptor is expressed at high levels in the lung and intestine representing the portals of 
entry for pathogens [92, 96]. Expression levels of Dectin-1 can be significantly 
influenced by a variety of cytokines and biological response modifiers such as β-glucan, 
GM-CSF and dexamethasone [93, 97, 98].  
 
Dectin-1 has a similar structure to other CTLRs but in contrast to many of these receptors 
lacks cysteine residues in the stalk region, which are required for dimerization, indicating 
that the molecule is expressed, and functions as a monomer [39]. Dectin-1 is also N-
glycosylated, like most CTLR, this post-translational modification contributes to the 
receptor’s surface expression and function [99]. Both human and mouse Dectin-1 are 
alternatively spliced generating two major and a number of minor isoforms. The major 
isoforms possess altered functions and differ by the absence or presence of a stalk region 
[74, 100]. In a recent report, one of the minor human isoforms E (hDectin-1E) that lacks 
the stalk and transmembrane regions, was located in the cytoplasm and was shown to be 
capable of interacting with a cytoplasmic scaffold protein, Ran Binding Protein in the 











Dectin-1 was the first example of an NKCL receptor whose primary ligand is a 
polysaccharide and not a protein [29]. Dectin-1 recognizes soluble and particulate β-
glucans from fungi, plants and bacteria in a calcium-independent manner, and is the 
primary receptor for these carbohydrates on leukocytes [29, 102-104]. Although there are 
other receptors for β-glucans [105], Dectin-1 is the primary receptor for β-glucans on 
leucocytes [29, 106, 107]. Dectin-1 specifically recognizes 1,3-linked β-glucans and not 
monomers or polymers with other linkages [29, 108]. The crystal structure of the CTLD 
of Dectin-1 has been determined and mutational analyses have showed that two residues 
Trp221 and His223, are essential for β-glucan binding, and these two residues flank a 
groove on the CTLD which could be a potential binding site [109, 110].  Structural 
analysis of this receptor revealed that Dectin-1 might dimerize through a novel interface, 
creating another binding site for β-glucan [110].  
 
Dectin-1 has the ability to recognize other ligands on mycobacteria and on T-cells, which 
do not express β-glucans [111-113]. The recognition of T-cells by Dectin-1 is not 
inhibitable by β-glucans, suggesting that this receptor has two independent functional 
binding sites [74]. There Dectin-1 can stimulate activation and proliferation of T-cells, 
implying that it may function as a co-stimulatory molecule on APCs [39, 74, 114]. The 
expression of Dectin-1 by APCs in the T-cell area of lymphoid tissues supports the 
function of this receptor in these interactions [96]. The endogenous ligand of Dectin-1 
has not been identified, although it may be a protein, which interacts through a distinct 











involved in the recognition and uptake of apoptotic cells and in the cross-presentation of 
cellular antigens [115]. 
 
Most of the cellular responses induced by Dectin-1 have been determined using zymosan, 
a particulate fungal-derived cell wall fraction from Saccharomyces cerevisiae. The 
function of Dectin-1 has been examined, more recently, by using highly purified β-
glucans, such as curdlan and particulate glucan, there are also methods available to 
remove the contaminants from zymosan [103, 116, 117]. Utilizing these various β-
glucans, shows that Dectin-1 induce ligand uptake by endocytosis and phagocytosis [51], 
the respiratory burst [106, 118], and the production of various cytokines and chemokines 
[103, 118-121]. Dectin-1 is sufficient for most of these responses, others, such as the 
production of inflammatory cytokines and the respiratory burst, however, are enhanced 
by the cooperative signaling from Myd88 coupled TLRs [118, 119, 122]. This was the 
first example of collaborative induction of cellular responses between a non-TLR and 
TLRs. Furthermore, Dectin-1 ha  the ability to induce cytokines, such as IL-23, which 
has been shown to directly couple the innate and adaptive immunity, independently from 
the TLRs [103].  
 
The cytoplasmic tail of Dectin-1 contains an ITAM-like motif (YxxL), which resembles 
the tandem repeat sequence found in other activation molecules, such as DAP12, Fc 
receptors and lymphocyte antigen-receptor complexes [123]. The ITAM-like motif of 
Dectin-1 becomes tyrosine phosphorylated upon ligand binding by Src family kinases, 











membrane-proximal tyrosine within the ITAM-like sequence of Dectin-1 is required for 
signaling dexamethasone to require two phosphotyrosines for binding [51, 120]. 
Although the mechanism is still unclear, signaling is possibly initiated following the 
bridging of two Dectin-1 monomers [120, 124]. This was the first example of a single 
tyrosine based sequence being able to signal via Syk. This phenomenon has subsequently 
been shown to occur in other CTLRs, such as CLEC-2 [125]. The downstream signaling 
from Syk involves the novel adaptor CARD9, and activation of MAP kinases and NfκB 
[120, 126-128]. 
 
Syk is the central kinase involved in most of the Dectin-1 mediated cellular responses, 
but there are also Syk-independent pathways of the receptor signaling which may be cell-
type specific. For example, Dectin-1 dependent phagocytosis in macrophages does not 
involve Syk, yet this kinase is partially required for particle uptake in DCs [51, 120]. The 
Syk-independent signaling is most likely involved in novel pathways, which are largely 
still uncharacterized [51]. 
 
The cell walls of fungi consist of up to 50% β-glucan, and the identification of Dectin-1 
as a receptor for these carbohydrates suggested a role in anti-fungal immunity [129, 130]. 
Dectin-1 can recognize a number of fungal species including Coccidiodes [131], 
Aspergillus [132-134], Candida [119, 135], Pneumocystis [121] and Saccharomyses 
[119, 136]. Characterizing the interaction of these organisms in vitro with transfected and 











including fungal internalisation and killing [121, 135, 137], cytokine and chemokine 
production [103, 119-121, 131, 132].  
 
The recognition of fungi by Dectin-1 also triggers the production of non-protective 
cytokines, such as IL-10 and IL-23, the reasons for this are unclear [103, 120]. The 
induction of IL-23 contributes to the development of Th17 adaptive responses, which 
impair anti-fungal immunity by inhibiting protective Th1 responses and the promotion of 
inappropriate inflammation [138]. Dectin-1 induces the production of IL-10, this cytokine 
inhibits anti-fungal immunity, however the production of IL-10 through this pathway 
may be required to help reduce inflammatory pathology and to promote fungal 
persistence and long-term immunity [139-141]. 
 
The role of Dectin-1 in vivo has mixed results, which might be due to the use of knockout 
(KO) mice on different genetic backgrounds [142, 143]. On a 129Sv background, Dectin-
1 KO mice, displayed increased susceptibility to systemic infection with Candida 
albicans, due to inflammatory defects and reduced fungal killing [107]. Conversely, 
Dectin-1 defiecient mice on a C57BL6 background were not susceptible to Candida, but 
there were some differences observed in fungal burdens during infection with 
Pneumocystis carinii, which resulted from defects in the respiratory burst [142]. The 
overall results support a role for Dectin-1 in anti-fungal immunity in vivo. The discovery 
of Dectin-1 and the study of its functions highlight a key role in innate anti-fungal 
immunity and is the first example of a signaling non-Toll-like PRR involved in the 











The discovery of this receptor has provided some fundamental insights into the molecular 
mechanisms underlying the activity of β-glucans, and has extended the understanding of 
the functioning of the innate immune system. This receptor mediates various cellular 
functions, from fungal binding, uptake and killing to the induction of various cytokines 
and chemokines. The use of Syk to mediate the majority of these cellular responses has 
implications for the role of other CTLRs in immunity. 
 
1.7.2 LOX-1 (CLEC8A, OLR1)  
LOX-1 was initially discovered as an endothelial-specific scavenger receptor for oxidized 
low-density lipoproteins (Ox-LDL) and was the first member of the ‘Dectin-1 cluster’ to 
be identified [144]. The LOX-1 protein is well characterized and is the sole member of 
the class E scavenger receptor (SR) subgroup [145]. The extracellular domain of LOX-1 
includes two N-glycosylation sites, three intra-molecular disulfide bonds, and two 
cleavage sites for membrane bound LOX-1, whereby soluble LOX-1 (sLOX-1) can also 
be released [146]. N-glycosylation of LOX-1, is a posttranslational modification which 
contributes to cell-surface expression and ligand recognition [147]. LOX-1 has the 
potential to form a homodimer through its disulfide bond, which promotes the 
multimerization of this receptor, enhancing ligand binding [148]. The C-type lectin-like 
fold of LOX-1 is highly conserved within the mammalian species [149].  
 
The expression of LOX-1 on a cellular level has been observed in immature myeloid 
DCs, macrophages [76], monocytes, vascular smooth muscle cells [150], platelets and B 











oxidative and mechanical stimuli during certain pathological conditions in vivo, including 
atherosclerosis, hypertension, hyperlipidemia and diabetes [151, 152]. Furthermore, the 
expression of LOX-1 can also be upregulated following inflammatory stimuli such as 
TNF-α, LPS, and fluid shear stress [75, 153]. Importantly, the binding of LOX-1 to Ox-
LDL leads to the upregulation of receptor expression, which may aggravate the 
development of LOX-1 mediated diseases such as atherosclerosis [154].  
 
 
LOX-1 recognizes multiple diverse ligands in addition to Ox-LDL, including gram-
positive and gram-negative bacteria, such as S.aureus and E.coli [155], anionic polymers 
such as carrageenan [75], anionic phospholipids including phosphatidylserine [156], 
apoptotic and aged cells [52], activated platelets [157] and advanced glycation end-
products (AGEs) [155]. The ligand recognition of LOX-1 is thought to involve 
electrostatic interactions with positively charged residues exposed on the surface of the 
CTLD of the receptor with negatively charged regions of the ligands [151, 158]. The 
diversity in ligands recognized by LOX-1 shows that this receptor has a versatile role in 
its physiological functions.  
 
LOX-1 lacks the classical signaling motifs in its cytoplasmic tail, but can still mediate 
various cellular functions, including endocytosis, phagocytosis, cytokine production, 
apoptosis, the activation of NFκB and the production of ROS [151, 152, 158]. 
Additionally, LOX-1 can act as an cell-adhesion molecule involved in leukocyte 











LOX-1 is involved in Hsp70-mediated antigen cross presentation [159]. The signaling 
pathways leading to these cellular responses are not fully understood, although various 
downstream components have been implicated, including phosphoinositide 3-kinase, p38 
mitogen activated protein kinase (MAPK) [158], protein kinase C (PKC) [30] and protein 
tyrosine kinase (PTK) [11] and transcription factor NF-κB [39]. In a recent study, LOX-1 
mediated internalization of Ox-LDL was shown to occur through a clathrin-independent 
mechanism involving a novel cytoplasmic tri-peptide sequence motif of the receptor 
[160]. 
 
The major focus in LOX-1 was the interest in its involvement in vascular disease and the 
role of this receptor in the development of atherosclerosis. Various responses that are 
mediated by LOX-1 have been linked to the pathological, pro-atherogenic, changes in the 
vascular endothelium, and upregulation of LOX-1 in atherosclerotic lesions could result 
in a positive feedback system that promotes the development of atherosclerosis [151, 
158]. In addition, increased relea e of soluble LOX-1 has been anticipated to be a marker 
for acute coronary syndrome. The LOX-1 KO mouse model supports a role for this 
receptor in the development of atherosclerosis [154, 161]. There is some evidence that 
LOX-1 may be involved in myocardial ischemia reperfusion injury, thrombosis, 
hypertension and may also be involved in generating inflammatory responses during 
microbial infection [158, 161]. 
 
LOX-1 has the ability to recognize a broad range of structurally diverse ligands, mediates 











cytoplasmic tail, and is involved in the development of various diseases. These special 
features of LOX-1 have extended the understanding of the diverse functional abilities of 
CTLRs and the importance of these receptors in homeostasis and immunity. 
 
1.7.3 CLEC-1 (CLEC1A)  
CLEC-1 and CLEC-2 were originally identified simultaneously as NKC-related lectins 
[162]. There is not much known about CLEC-1 in comparison with the other ‘Dectin-1 
cluster’ receptors. CLEC-1 contains two extra cysteine residues in the CTLD, in addition 
to the six conserved cysteine residues. The stalk also contains a cysteine residue, 
although its not confirmed whether CLEC-1 is able to undergo homo- or 
heterodimerizations. Another interesting feature of CLEC-1 is the presence of a tyrosine 
residue in the predicted cytoplasmic domain. The intracellular tyrosine of CLEC-1 was 
found within the sequence YxxT and may represent a novel immunoreceptor tyrosine-
based motif [46]. CLEC-1 mRNA expression is predominantly expressed in human 
placenta and lung and to a lesser extent in thymus and heart. High levels of CLEC-1 were 
detected by RT-PCR in DCs stimulated with TNF-α or by CD40-CD40 ligand 
interaction. CLEC-1 expression is absent in peripheral blood monocytes (PBMC), 
granulocytes, B-, T- or NK-cells and expressed to a lesser extent monocytes. CLEC-1 
appears to be selectively expressed as at least two splice variants in activated DCs. In 
another independent study CLEC-1 mRNA was found to be significantly expressed in 
HUVEC (endothelial cell line derived from human umbilical vein endothelium) at a level 
comparable to primary DCs [68]. CLEC-1 cannot to be transported to the cell surface of 











molecule for its surface expression [162]. The ligand for CLEC-1 has not yet been 
identified and the physiological role of this receptor is yet to be determined. 
 
1.7.4 CLEC-2 (CLEC1B)  
This receptor was originally cloned from bone marrow and is preferentially transcribed 
primarily in the liver and PBMC, bone marrow cells, and myeloid cells [162]. The 
murine CLEC-2 shares 60% identity with the human homologue and is expressed on 
platelets and megakaryocytes [125, 162]. mCLEC-2 in platelets undergo differential 
glycosylation, consistent with the presence of three N-glycosylation sites [101]. Recently 
two novel splice variants of mCLEC-2 have been identified. The two variants are derived 
from the omission of exon 2 and 2/4, and each has a different expression profile and 
subcellular localization, in comparison with the full-length mCLEC-2 [163]. 
Additionally, the full-length mCLEC-2 has the ability to be cleaved into a soluble form, 
and both membrane-bound as well as soluble mCLEC-2 exist as homodimers [163]. 
 
The activation of CLEC-2 triggers platelet aggregation and activation, this activity is 
mediated by the ITAM-like motif of CLEC-2 [125]. This signaling motif resembles that 
found in Dectin-1, and can also recruit and signal via Syk [125]. In addition to Syk, the 
signaling pathway activated by CLEC-2 includes Tec family kineses, Src, PLCγ and 
Rac1 [124, 164]. 
 
An exogenous ligand of CLEC-1 has been identified as the snake venom toxin, 











induce CLEC-2 clustering to trigger downstream signaling and platelet activation [165-
167].  CLEC-2 has also been shown to bind HIV-1 [101], and may  capture and transfer 
infectious HIV-1 in cooperation with DC-SIGN [168]. 
 
Several studies have identified podoplanin, a mucin-type sialoglycoprotein, expressed on 
tumor cells as an endogenous ligand for CLEC-2 [77, 169].  A recent study showed that 
the monomeric extracellular domain of human CLEC-2 binds to podoplanin to a lesser 
extent than the multimeric one [169]. Dimerization or multimerization has been shown to 
be an efficient way to enhance the recognition of ligands for soluble and cell surface 
receptors [14].  The interaction of CLEC-2 with podoplanin is proposed to involve O-
glycans, which may be involved in promoting tumor growth and/or metastasis, and could 
therefore be a possible target for therapeutic intervention [77, 169, 170]. 
 
CLEC-2 is the first CTLRs shown to activate platelets through a Syk-dependent manner, 
which is similar to the Dectin-1 signaling pathway for activation. This indicates that other 
CTLRs may also use similar signaling pathways for activation. Although endogenous and 
exogenous ligands for CLEC-2 have been identified, the physiological role of this 
receptor is yet to be defined. 
 
1.7.5 MICL (CLEC12A)  
MICL (CLEC12A) was identified as an inhibitory receptor, predominantly expressed on 
myeloid cells, granulocytes and monocytes as a heavily glycosylated monomer [171, 











C-type lectin-like molecule-1 (CLL-1), Dendritic-cell-associated C-type lectin 2 (DCAL-
2) and Killer cell lectin-like receptor 1 (KLRL1) [176, 177, 178]. The murine MICL 
receptor is structurally and functionally similar to the human orthologue, with some 
notable differences. mMICL is expressed as a dimer and is not glycosylated, but it is 
expressed primarily on myeloid cells like the human receptor [122]. Human MICL is 
variably spliced, generating at least three alternatively spliced isoforms identified in 
peripheral blood leukocytes (MICL-α, -β and –γ respectively) [171]. The expression of 
MICL is downregulated following inflammatory conditions, including responses 
triggered by microbial components [171, 172, 175]. MICL has also been identified as a 
marker for acute myeloid leukaemia in humans [176]. 
 
MICL can recruit inhibitory phosphatases (e.g. SHP-1 and SHP-2, but not SHIP) upon 
activation. These signaling events occur through the single ITIM sequence (VxYxxL) in 
the cytoplasmic tail of MICL and has the ability to inhibit cellular activation [171, 175, 
177]. Although MICL is not expressed on NK cells, it has also been reported to inhibit 
NK cell cytotoxicity [177] and antibody mediated cross-linking of MICL on human 
monocytes-derived DCs has been shown to affect the function of DCs, by altering the 
cytokine production, cellular maturation and chemokine receptor expression, indicative 
of a role for this receptor in the control of immune responses [178].  
 
There is some evidence for an endogenous ligand(s) for murine MICL and this was done 











molecule is still unknown [175]. The presence of an endogenous ligand(s) in multiple 
mouse tissues, suggests that MICL plays a role in homeostasis [175].  
 
1.7.6 CLEC12B (Macrophage antigen-H) 
CLEC12B (Macrophage antigen-H) was identified by its homology with NKG2D related 
molecules [179]. Unlike NKG2D however, the putative CLEC12B protein does not 
contain a charged amino acid in its transmembrane region but an ITIM sequence 
(VxYxxL) in the cytoplasmic tail [180], similar to that of MICL [171]. RT-PCR of 
CLEC12B in human cDNA libraries showed that this receptor is not expressed on 
primary T cells, NK cells or NK cell lines. The PCR results were obtained from an 
enhanced RT-PCR indicating that CLEC12B is expressed at very low levels. In 
mammary gland and ovary a truncated splice variant was found lacking exon 4, which is 
part of the CTLD, indicating that this alternative transcript could possibly yield a non-
functional protein. 
 
Human CLEC12B is expressed at the cell surface forming a homodimer in transfected 
cells. The protein expression of CLEC12B was found on in vitro differentiated 
macrophages and on PMA (Phorbol 12-myristate 13-acetate) stimulated monocytes 
(U937 cell line), but not on unstimulated cells. The ligand for CLEC12B has not yet been 
identified, however, it is able to function as an inhibitory receptor and is dependent on the 
ITIM sequence for this activity. CLEC12B signals via the recruitment of the 











artificial model system, CLEC12B was able to inhibit certain cellular functions [179]. 
More functional analysis is required to understand the physiological role of CLEC12B. 
 
1.8 CLEC9A 
CLEC9A is a novel uncharacterized CTLR that is part of the ‘Dectin-1 cluster’ and is the 
focus of this thesis. Subsequently, two other independent publications on CLEC9A 
(called DNGR-1, Dendritic cell NK lectin Group receptor-1, by one group) appeared and 
the data from each of these publications will be mentioned and discussed throughout the 
thesis. 
 
1.8.1 Aims of this thesis 
The aim of this thesis was to characterize a novel group V CTLR, called CLEC9A, which 
is part of the ‘Dectin-1 cluster’, for both human and mouse, and to determine its 
functional role in immunity and/or homeostasis. The objectives were: 
 
1. To make use of in silico analysis to determine the primary and secondary 
structure of CLEC9A and determine functional similarity CLEC9A might share 
with other known receptors, 
2. To characterize the expression profile of the receptor,  
3. To determine the intracellular signaling events and function of CLEC9A, and 














Materials and Methods 
 
2.1   Cells 
 
2.1.1 Cell lines used  
All cell lines were obtained from the IIDMM cell bank at UCT, and were cultured 
according to ATCCa recommendations. A summary of all the cell lines and their growth 
conditions used specifically for this study are listed in Table 2.1. 
 
2.1.2 General cell culture 
Each cell line was grown in the appropriate media and unless stated otherwise, media 
were supplemented with 10% heat-inactivated (HI) fetal calf serum (FCS) (from Sigma), 
100units/ml penicillin, 0.1mg/ml streptomycin, and 2mM L-glutamine (referred to as 
RPMI10 or DMEM10). Cells were cultured on tissue culture plastic flasks/plates in a 5% 
CO2 humidified incubator, or in sealed, gassed flasks at 37˚C and routinely passaged after 
every 3 to 4 days in culture. Adherent cells were detached either with Trypsin/EDTA or 








































Cell line Augmentation  Media used 





















RAW 264.7: murine 
macrophage cell line derived 







293T: derivative of the 












Y3: rat myeloma cell line Non-adherent RMPI 
Phoenix eco (ÖNXeco): 




























2.1.3 Isolation and culture of human monocytes and in vivo derived 
macrophages/DCs 
To obtain non-adherent mononuclear cells, monocytes, macrophages or DCs, 25ml of 
blood (obtained from Western Province Blood Transfusion Service, Cape Town, South 
Africa) was diluted 1:1 in room temperature PBS and 35ml of this was layered over 15ml 
solution of Ficoll-Hypaque (from Amersham) and spun at 900g at RT, for 20 minutes 
with no brake, 10ml serum was then removed, heat inactivated at 56˚C for 30 minutes, 
centrifuged at 1250g for 10 minutes, and 0.22μm filtered. The autologous serum was 
used at 1% in X-VIVO10 medium (supplied supplemented with phenol-red and 
gentamycin) (from Invitrogen). The layer of mononuclear cells in the Ficoll-Hypaque 
was aspirated (including those adherent to the side of the tube), clumps were disrupted by 
vigorous pipetting and subsequently washed with ice cold PBS (made up to 50ml) 
pelleting at 500g for 7 minutes at 4˚C with low brake. The cells were washed 3-4 more 
times in PBS and once in RPMI, all with centrifugation at 250g, 4˚C for 5 minutes using 
full brake. The final pellet was resuspended in X-VIVO with serum and evenly spread on 
15cm Petri dishes that had been pre-coated with 2% sterile gelatine (from Sigma). 
Following 90 minutes incubation at 37˚C, non-adherent mononuclear cells (mainly 
lymphocytes) were gently washed off with warm RPMI, 3 or 4 times. The monocytes 
remained adherent and were replaced in the incubator with fresh X-VIVO/serum 
overnight. Subsequently the monocytes were detached by gently washing with PBS and 
placed on ice. These monocytes were centrifuged at 350g for 10 minutes at 4˚C and 











Sigma), and plating for future experiments. For FACS analysis of macrophages and DCs, 
cells were plated in 48 well plates. 
 
2.1.4 Isolation of peripheral blood leukocytes 
For flow cytometric analysis of CLEC9A expression, 2ml peripheral blood was collected 
in 4mM EDTA to prevent coagulation, erythrocytes were lysed by adding 10ml ice cold 
fresh Gey’s solution and 2ml FCS was then under laid [92]. The sample was centrifuged 
for 10 minutes at 300g with low brake, the supernatant discarded and the process 
repeated. The final pellet was resuspended in 1ml cold FACS wash and the cells were 
counted using Trypan blue. 
   
2.2  General methods 
All routine nucleic acid manipulation techniques were performed essentially as described 
by Sambrook, et al. [181]. 
 
2.2.1 Polymerase chain reaction (PCR) 
All PCR reactions co tained dATP, dTTP, dCTP and dGTP at 0.2mM each, appropriate 
primers at 0.2μM, 1.5mM MgCl, 1x manufacturer’s PCR buffer (20mM Tris-HCl pH8.4, 
50mM KCl: 10 x stock), 0.5 units Taq polymerase (from BD Bioscience) and ~100ng of 
template DNA per 20-50µl reaction and were incubated using a Gradient PTC-200 Peltier 
thermal cycler (from MH Research). Parameters for DNA amplification were dependent 
on primers and the template length, standard parameters involved a denaturing step at 











(72ºC for 1.5 minutes per 1Kb of template). Annealing temperatures were set at 5ºC less 
than the melting temperature (Tm) of the annealing portion of the primer. After cycling, 
the reaction was incubated at 72ºC for a further 5 minutes and then maintained at 4ºC. 
Each reaction was analyzed by agarose gel electrophoresis or stored at -20ºC. 
 
High fidelity PCR reaction was used to amplify cDNA for cloning using Advantage-HF2 
polymerase (from Clontech) and the kit buffers according to the manufacturer’s protocol. 
Cycling parameters were as above, but with extension at 68˚C. 
 
2.2.2 Agarose gel electrophoresis 
Agarose gels were prepared by dissolving electrophoresis grade agarose (from WhiteSci) 
under high temperature in 0.5 x TBE buffer to a final concentration of 0.8%. ethidium 
bromide (from Sigma) was added to the dissolved agarose to a final concentration of 
0.2µg/ml. DNA loading dye was added to the samples before they were loaded onto the 
gel. DNA molecular weight marker was added for identification of fragments of specific 
size. Gels were run at a constant voltage of 90-100V, to give a good separation of 
fragments. The gels were analyzed with using a long wavelength (366nm) UV 
transilluminator (from UV Wirsam Scientific). 
 
2.2.3 Purification of DNA from agarose gels 
DNA fragments were excised from agarose gels using a long wavelength UV 
transilluminator, weighed and extracted from the agarose using SV gel and PCR 











2.2.4 Plasmid digestion 
Digestion of plasmid vectors containing DNA inserts was preformed using appropriate 
restriction enzymes according to manufacturer’s protocols and guidelines on the usage of 
each enzyme regarding temperatures and buffers. In general 25-50ng plasmid DNA was 
digested for 2 hours (or overnight) at 37ºC to ensure maximal digestion. The digestion 
reaction of some enzymes was terminated by heat inactivation of the enzyme at the 
appropriate temperature according to the manufacturer’s protocol. In the situation when 
plasmids needed to be digested with two different restriction enzymes, manufacturer’s 
protocols were consulted to determine whether both enzymes digestions could be 
performed in the same buffer. When this was not possible, sequential digestions were 
performed with the DNA being gel purified before the second digest was performed. The 
success of each digest was confirmed by gel electrophoresis, thereafter the desired insert 
or cut vector was cut out, and gel purified. 
 
2.2.5 Plasmid dephosphorylation 
Sometimes it was necessary to dephosphorylate cut vectors using 2U of shrimp alkaline 
phosphatase (from Fermentas) in the presence of manufacturer-supplied buffer to 
enhance the ligation. The reaction was incubated at 37°C for 60 minutes and then heat 
inactivated at 65°C before phenol/chloroform extraction. 
 
2.2.6 Phenol/chloroform extraction of DNA 
To remove protein contaminants, an equal volume of phenol was added to the nucleic 











minutes, the aqueous phase was transferred to a sterile eppendorf tube. An equal volume 
of chloroform:isoamyl alcohol (24:1) was added to the aqueous phased and mixed by 
vortexing. Sample was centrifuged at 13,000rpm for 2 minutes and aqueous phase 
transferred to a clean 1.5ml eppendorf tube. The nucleic acid was precipitated using 0.1 
volume of 3M sodium acetate, pH 5.2 and 2 volumes isopropanol and stored at -20˚C or 
pelleted by centrifugation at 13,000rpm for 15minutes at 4˚C and then washed in 70% 
ethanol to remove residual salts. After air-drying, the nucleic acid pellets were 
resuspended in TE buffer. 
 
2.2.7 Ligation of plasmid vectors and insert DNA 
For all ligation reactions, 25-50ng of plasmid was ligated with 50-250ng insert DNA in 
20µl final volume containing 1U T4 DNA ligase (from Fermentas) and the manufacturers 
supplied buffer. Controls with no insert and/or no plasmid were included to observe false-
positive background, to exclude self-ligation of vector or the presence of contaminating 
plasmids. Ligations were performed overnight at 16ºC. The ligation of PCR products was 
done by TOPO cloning (from Invitrogen) kit according to manufacturer’s protocol. 
 
2.2.8 Butanol precipitation  
Butanol precipitation was performed after ligation for the removal of contaminants, 
which might influence the transformation competency. For each 20µl ligation mix 30µl 
dH2O and 500µl butanol was added, vortexed for 10 seconds and centrifuged at 
13,000rpm for 10 minutes at 4ºC. Supernatant was discarded and pellet containing 











2.2.9 Transformation and colony selection 
Top10 competent E. coli (from Invitrogen) were stored at -80ºC until use. These cells 
were thawed on ice and kept on ice throughout the transformation process. A volume of 
12µl competent cells was added to 2µl plasmid DNA and incubated on ice for 10 
minutes. The cells were heat shocked at 42ºC for 30 seconds and placed back on ice 
before adding 250µl SOC. The reaction mix was incubated at 37ºC on a shaking platform 
at 300rpm for 45 minutes before being plated on pre warmed ampicillin-containing 
(100µg/ml) agar plates and incubated overnight at 37ºC. 
 
All the vectors used contained an ampicillin resistant cassette to ensure that only those 
bacteria containing the successfully ligated plasmids could grow on the ampicillin 
containing agar plates and the bacteria that lack the ampicillin resistant cassettes do not. 
Incubation times were kept short and colonies were carefully selected to avoid satellite 
colonies. Colony PCR was used to identify colonies with correctly ligated inserts. 
Positive colonies were mini-prepped and tested by restriction enzyme digest and sent for 
sequencing. 
 
2.2.10 Colony PCR 
Colonies were screened by PCR prior to selection to confirm that the colony carried an 
insert in the desired orientation. Single colonies were sampled from ampicillin agar plates 
with a pipette tip, and transferred to a master plate and numbered for later identification 
of the ones yielding positive results. Thereafter the colonies were transferred directly to a 











using the primers designed to amplify the insert of interest only if in the correct 
orientation. Colonies that tested positive for the desired insert were selected and 
inoculated for mini-prepping and sequencing. 
 
2.2.11 Plasmid mini-prep 
In order to generate enough plasmid DNA for analysis by restriction enzyme digest and 
sequencing, only the positive PCR colonies were selected for inoculation. Colonies were 
picked from the master plate with a pipette tip and added to 10ml LB broth containing 
100μg/ml ampicilin and incubated at 37ºC shaking overnight. Aliquots of 0.6ml culture 
was resuspended with 30% glycerol and stored at -20ºC for future use. The remaining 
9.4ml of the original culture was pelleted at 3,500rpm for 5 minutes and processed using 
a SV Mini-prep Kit (from Promega). Purified plasmid DNA was analyzed by sequencing 
to confirm the fidelity of the inserted sequence. 
 
2.2.12 Isolation of genomic DNA 
The genomic DNA was isolated from the newly generated cell lines to confirm that the 
cells were expressing the entire sequence introduced by retroviral transduction. Cells 
were detached with lidocaine/EDTA, pelleted at 850rpm for 5 minutes at 4ºC and lysed in 
cell lysis buffer (CLB), which had been supplemented with 50µg/ml Protease K (from 













Genomic DNA was extracted by adding an equal volume of phenol to the lysates, 
followed by vigorous shaking and centrifuged for 2 minutes at 13,000rpm at 4ºC. 
Supernatants were removed and placed in new 1.5ml eppendorf tubes. An equal volume 
of chloroform:isoamyl alcohol was added and the tubes were inverted 4 times and 
centrifugation repeated. The aqueous phase was transferred to a new eppendorf tube, 1/10 
volume 3M sodium acetate pH 5.2 was added followed by an equal volume of 
isopropanol. After a gentle shake the DNA was cooled at -20ºC to allow precipitation of 
DNA. Pelleted DNA was washed with 70% ethanol, air dried and resuspended in TE 
buffer prior to use. The sequence integrity was established by PCR using appropriate 
primers that flank the retroviral insert. Empty vector transduced cells served as a negative 
PCR control. 
 
2.2.13 Isolation of RNA and reverse-transcription 
Cells obtained after FACS-based sorting were snap frozen in liquid nitrogen and stored at 
-80°C, until ready for use. All pipettes and surfaces were cleaned with RNase-away (from 
Fluka). For every 100mg of tissue 1mL Trizol (from Invitrogen) was added and 
homogenized at RT. After 5 minutes at RT 0.2ml chloroform was added to the Trizol mix 
followed by vigorous shaking for 15 seconds and incubated for 3 minutes at RT. The 
samples were centrifuged at 12,000g for 15 minutes at 4°C. The aqueous phase 
containing the RNA was transferred to a new eppendorf tube and 0.5ml isopropyl alcohol 
was added and incubated at RT for 10 minutes to precipitate the RNA. The RNA pellet 
was washed with 70% ethanol, air dried and re-dissolved in RNase Free H2O (from 











260nm. For long-term storage 0.25M sodium acetate and 2.5 times volume 100% ethanol 
was added to the RNA and stored at –80°C.  
 
2.2.14 Formaldeyde gel electrophoresis gel 
Formaldehyde gels were prepared by dissolving 1g electrophoresis grade agarose in 10ml 
10x MOPS buffer. After the gel cooled down to RT, 5.4ml 37% formaldehyde was added 
and left to solidify in the fume hood. RNA loading dye was added to 5-15μg RNA and 
boiled for 2 minutes before it was loaded onto the gel. The gel was covered with 1x 
MOPS buffer containing ethidium bromide. Gels were run at a constant voltage of 90-
100V, to give a good separation of fragments. The gels were analyzed using a long 
wavelength (366nm) UV transilluminator. The presence of 28S and 18S indicated the 
isolation yielded a good quality of RNA. 
  
2.2.15 SDS-Polyacrylamide gel electrophoreses (PAGE) 
Protein concentrations of cell extracts were measured at OD 280nm using the 
spectophotometer (from NanoDrop Technologies Inc.). Samples of approximately 25µg 
protein were mixed with sample buffer (reduced or non-reduced), boiled for 5 minutes at 
95ºC, and 20µl per well were loaded into a 10% polyacrylamide stacking gel (pH 6.8) 
and resolved on a 10% acrylamide gel (pH 8.8) alongside molecular weight markers. 
Gels 1.5mm thick were cast and run in SDS running buffer using a Mini- PROTEAN III 
gel system (from BioRad) at a constant voltage of 100-200V as long as required for good 
separation.  Gels were subsequently used in western blots, or analyzed by Coomasie 











2.2.16 Antibody purification and biotinylation 
For the production of antibody stocks from hybridomas, cells were grown up in RPMI20 
and allowed to grow until the medium was exhausted. Supernatants were cleared of 
cellular debris by centrifugation at 1,000g for 10 minutes and were then 0.22µm filtered. 
Filtered supernatants were run over a Protein G Sepharose beads (from Amersham) 
column and fractions of purified antibody were eluted from the column using 2 volumes 
of 50mM glycine pH 2.5 into one volume of 1M Tris pH 8 to neutralize the elution 
buffer. The fractions containing the highest antibody concentrations were pooled, injected 
into a 10kDa cut off dialysis cassette (from Pierce) and dialysed overnight in PBS. 
Quantification of antibody concentration was repeated by using the spectophotometry and 
BCA protein assay (from Pierce). Purified antibodies were used at 10µg/ml and were 
tested by flow cytometry and Western blot. 
 
A protocol supplied by S Cobbold (Oxford)b was used to biotinylate antibodies. Purified 
antibody was dialysed into bicarbonate buffer, and diluted to 1mg/ml. This was incubated 
with 37µl Sulfo-NHS-LC-Biotin (from Pierce) per ml in a glass bottle at 4ºC overnight. 
All conjugated antibodies were dialysed extensively into PBS and tested by flow 
cytometry before use. 
 
2.2.17 Purification of polyclonal antibody 
We generated a soluble Fc-mCLEC9A protein to immunize rats for the generation of 
polyclonal antibodies against the mCLEC9A receptor. The generation of this protein is 
described in section 2.5.3. The Fc-mCLEC9A soluble protein was dialysed in coupling 












buffer overnight at 4°C. For coupling, 1g cyanogen bromide resin (CNBr) (from Sigma) 
per 1mg Fc-mCLEC9A, was used. The resin was washed, using a Büchner, for 30 
minutes with 200ml 1mM HCL, 250ml dH2O and 5ml coupling buffer and transferred to 
the dialysed Fc-mCLEC9A protein to be rotated overnight at 4°C. All the unreacted 
ligand was washed away with coupling buffer and the resin was blocked in 0.2M glycin 
pH 8 for 2 hours at RT. The resin was washed extensively with coupling buffer, then 
0.1M acetate buffer pH4 and lastly with 0.5M sodium chloride (NaCl) to remove the 
blocking solution.  
 
The serum collected from immunized rats was rotated with 50µg/ml hIgG (from Sigma) 
overnight at 4ºC to compete for Fc reactivity from anti-mCLEC9A polyclonal anitbody. 
Thereafter the sample was spun at 3,000rpm for 15 minutes at 4ºC and filtered through a 
serum filter (from PALL, Life sciences). Filtered serum was run over the CNBr/Fc-
mCLEC9A sepharose column and fractions of purified antibody were eluted from the 
column using 2 volumes of 50mM glycine pH 2.5 into one volume of 1M Tris pH 8 to 
neutralize the elution buffer. The elution fractions were measured at analyzed OD 280nm. 
The fractions containing the highest antibody concentrations were pooled, injected into a 
10kDa cut off dialysis cassette and dialysed overnight in PBS. Quantification of antibody 
concentration was repeated using the spectophotometry and BCA protein assay (Pierce). 















2.3 Transfection/transduction of cell lines and flow cytometry 
 
2.3.1 Transient transfection using Fugene 6 
The Fc-fusion plasmids (constructs described in section 2.6.2) were transfected into 
HEK293T cells using Fugene 6 (from Roche) according to the manufacturer’s protocol. 
Cells were plated out at 1 x 106 in 3mL DMEM10 the day prior to the transfection in a 6 
well plate. Supernatants were discarded and 2ml fresh DMEM10 was added. Cells were 
freshly cultured to 60% confluence and the transfections were performed in DMEM10. 
Trail transfections were usually done in 6 well plates but for the generation of large 
quantities of recombinant protein, T175 flasks were used and kept under 0.4mg/ml 
Zeocin (from Invitrogen) selection. 
 
2.3.2 Retrovirus production 
Inserts were excised from cloning vectors by restriction enzyme digestion and ligated into 
a retroviral vector, pFBneo (from Stratagene). Following ligation, colony selection and 
sequencing, vectors were transfected into a packaging cell line, Phoenix eco (ΦNXeco).c 
On Day 1 recently passaged ΦNXeco packaging cells were plated at 2x106 per well in 6 
well plates overnight in 3ml DMEM10 medium. The following day (Day 2) the medium 
was gently replaced to avoid detaching cells, to a final volume of 2ml per well. 
Packaging cells were then transfected according to the manufacturer’s protocol with 
Fugene 6 using 1µg DNA and 6µl Fugene per well (initially mixed with 94µl DMEM 
without serum) and incubated overnight at 37ºC. On Day 3, plates containing the 












transfected cells were transferred to a 32ºC incubator in a CO2-pulsed airtight container. 
On Day 4, supernatants were harvested and 5µg/ml polybrene (from Sigma) was added to 
reduce electrostatic repulsive forces between virus and target cell. Supernatants were then 
filtered through a 0.45µm filter and aliquots of 2ml were used immediately or stored in 
cryovials at -80ºC prior to use. 
 
2.3.3 Retroviral transduction and selection of cell lines 
On Day 1, target cells were plated at 2x106 for NIH3T3 or 2x105 for RAW264.7 cells 
(pre-treated with 0.2µg/ml tunicamycin (from Sigma) to enhance transduction efficiency) 
per well in 6 well plates overnight. The following morning, Day 2, cells were washed 
using fresh medium and replaced with 1.5ml of the filtered viral supernatants. Plates were 
then spun at 2,500rpm at 25ºC for 90 minutes to increase transduction efficiency [74]. 
Plates were then returned to the 37ºC overnight. On Day 3 the viral supernatants were 
replaced with fresh DMEM10 and on Day 4 the medium was replaced with selection 
medium: DMEM10 containing 600µg/ml G418. Cells were kept under selection until 
transduced colonies became clearly visible before transferring the cells to flasks. 
 
2.3.4 Flow cytometry 
In the majority of assays, cells were stained prior to fixation (referred to as ‘live’ and 
unpermeabilised) to preserve sensitive epitopes and to analyse only cell surface markers. 
Staining was performed at 4ºC to limit membrane mobility and cells were blocked with 
FACS block buffer to reduce non-specific staining. In experiments using RAW264.7 











specific background staining. Cells were either stained when still adherent (in 24 or 48 
well plates) or were first lifted with lidocaine/EDTA and then stained in V-bottomed 96-
well plates. All primary antibodies were used at 10µg/ml and cells were washed three 
times with FACS wash between staining steps. Secondary antibodies were used at 
between 1:100 and 1:200 dilutions. All monoclonal antibodies used were compared with 
staining by isotype-matched control antibodies. Incubation times were typically 60 
minutes for primary antibody and 45 minutes for secondary antibody staining. Stained 
cells were usually fixed in 1% formaldehyde prior to flow cytometry. Data were analyzed 
using Cellquest (from BD Bioscience). 
 
For fix-permeabilized flow cytometry staining, the cells were treated with 1% 
formaldehyde at 4°C for 30 minutes, before blocking with FACS block containing 0.05% 
saponin (from Sigma) for 30 minutes prior to the addition of antibodies. All primary 
antibodies were used at 10µg/ml and cells were washed three times with FACS wash 
between staining steps. Secondary antibodies were used at between 1:100 and 1:200 
dilutions. All monoclonal antibodies used were compared with staining by isotype-
matched control antibodies. 
 
2.4 Techniques specific to this study  
 











Sequence analysis was performed using various on-line toolsd. Sequences were aligned 
with Clustal X [182], dendrogram analysis and percentage identities were calculated by 
DNAMAN Version 4.0 (from Lynnon BioSoft). All graphs were generated in Microsoft 
Exel or GraphPad Prism, and all FACS analyses were performed using Cell Quest. 
Figures were compiled in Microsoft PowerPoint, and text in Microsoft Word. Images 
were processed using Adobe Photoshop version 6.0 and Multi-Analyst. 
 
2.4.2 Generation of cell lines and transduced cell lines  
The complete CLEC9A open reading frame (ORF) was isolated from human PBMC 
cDNA by PCR and cloned into the pFBneo (from Stratagene) retroviral vector containing 
an HA-tag [171] using the following primers:  5’AAAGAATTCCCACCATGCACGAGGA 
AGAAATATAC3’ and 5’AAACTCGAGGACAGAGGATCTCAACGC3’.  
 
C-terminally HA-tagged murine CLEC9A (mCLEC9A) was similarly cloned from mouse 
splenic cDNA using the following primers: 5’AAAGTCGACCACCATGCATGC 
GGAAGAAATA3’ and 5’GTACTCGACGATGCAGGATCCAAATGC3’. 
 
The CLEC9A/Dectin-1 chimera in pFBneo was generated using overlap extension PCR 
with primers: 5’CTGCTAAACTTTACAGAAAACCAC-AAGCCCACA3’ and 
5’TCTGGGCTTGTGGTTTTCTGTAAAGTTTAGCAG3’ such that the sequence translated 
as CLEC9A-79LLNFTECLEC9A-84/ Dectin-91NHKPTDectin-95. 
 
                                                 
d http:ca.expaxy.org 
  http://www.ncbi.nlm.nih.gov/BLAST/ 











The Fc-hCLEC9A expression construct was generated by PCR using the following 
primers: 5’TTTGGTACCAGCAGCAAGAAAAACTC3’ and 5’GCGGAATTCGAC 
AGAGGATCTCAACGC3’. Fc-mCLEC9A expression construct was generated using the 
following primers: 5’AAATGGTACCAGCAGGAAAGACTCATC3’ and 
5’AAAGAATTCGATGCAGGATCCAAATGC3’, both constructs were cloned into the 
pSecTag2 vector (from Invitrogen) upstream from the human IgG1 Fc region, generated 
as described [183].  
 
The fidelity of all constructs was verified by sequencing. Human and murine CLEC9A 
and isoforms have been deposited at GenBank under the following accession numbers: 
hCLEC9A, EU339276; mCLEC9A, EU339277; mCLEC9Aβ, EU339278; mCLEC9Aγ, 
EU339279; mCLEC9Aδ, EU339280; mCLEC9Aε, EU339281. 
 
To generate stable cell lines, constructs were packaged into virons, using HEK293T 
based Phoenix ecotropic cells, and the various cell lines were transduced as previously 
described in section 2.3.2. All cell lines were used as non-clonal populations to reduce 
founder effects and were generated and tested at least twice to confirm phenotype.  
Where required, cell lines were selected and maintained in 0.6mg/ml G418 or 4μg/ml 
puromycin (from Invitrogen). 
 
Human CLEC9A expression was analyzed by PCR of human tissue cDNA panels (from 
Clontech) using the following primers encoding the entire ORF, 5’ATGCACGAGGAA 











was analyzed by PCR of mouse tissue cDNA panels (Clontech) using the same murine 
primers described above.  Expression of G3PDH was used as a positive control using the 
following primers, 5’TGAAGGTCGGAGTCAACGGATTTG3’ and 5’CATGTGGGCCATG 
AGGTCCACCAC3’. 
 
2.4.3 The generation and testing of monoclonal antibodies (mAb) 
An eukaryotically-derived Fc-CLEC9A recombinant fusion protein was generated as an 
antigen for mAb generation for both human and murine CLEC9A as described above. 
This PCR product was obtained using the Fc specific primers and cloned into the 
KpnI/EcoRI sites of pSecTag2(C) vector (from Invitrogen) upstream of an ‘Fcmut’ 
construct designed by Dr. J Willment (UCT). This human Fc region does not fix 
complement or bind Fc receptors [184]. This was transiently transfected into 293T cells 
using Fugene 6 and viral packaging cells, and the supernatant harvested. The medium on 
the cells was replaced with medium containing zeocin (from Sigma) and a stable clone 
producing high levels of Fc-CLEC9A was isolated by clonal dilution and tested by anti-
Fc dot blotting. The soluble protein was isolated from the supernatants on a protein A 
column, extensively dialysed into tissue-cultured grade PBS and quantified by 
spectophotometry. The fusion proteins were used for the immunization of three BalbC 
mice (Fc-hCLEC9A) and three Wistar rats (Fc-mCLEC9A) between 4-6 weeks old. 
 
Immunization was performed by H Arendse (UCT) according to standard protocols 
[185]. A pre-bleed sample was taken to estimate background titer. Approximately 10μg 











sterile Fc-protein in sterile PBS and 25% Titremax Gold (from Sigma), and injected intra-
peritoneally. Two booster injections at 2 and 4 weeks later were administered and four 
days prior to splenocyte harvesting/fusion, 30μg Fc-CLEC9A was injected intravenously 
in PBS.  
 
A total of 5x107 NS1 myeloma cells were resuspended in 10ml RPMI (no serum) and 
kept at RT. The spleen was harvested and kept on ice in RMPI (no serum). Splenocytes 
were isolated by homogenizing the spleen through grinding it between two frosted glass 
slides with a circular motion to release splenocytes. The spleen cell suspention was 
filtered through a BD falcon cell strainer (from BD Bioscience) and collected into a 50ml 
falcon tube filled with RPMI (no serum). The splenocytes were washed twice with 
centrifugation at 1,200rpm at 25°C for 5 minutes. Approximately 1 x108 splenocytes 
were counted and resuspended in 10ml RPMI (no serum). The 5x107 myeloma cells were 
mixed with the 1x108 splenocytes to a total volume of 50ml RPMI (no serum) and 
centrifuged at 1,200rpm at 1,200rpm at 25°C for 5 minutes. The supernatant was discared 
and the tube containing the pellet was placed in a beaker water bath at 37°C. During the 
first 30 seconds 1.5ml of 50% polyethylene glycol (PEG) 1500 (from Sigma) was added 
drop wise, while agitating cell mixture by flicking the tube with finger throughout the 
whole procedure. The pellet was resuspended by gently pipetting for 30 seconds and after 
waiting for another 30 seconds 1 ml RPMI (no serum) was slowly added within 1 minute, 
this was the most critical step. Another 4ml RMPI (no serum) was slowly added within 2 
minutes, followed by slowly adding 5ml RPMI (no serum) over the next two minutes. 











discarded and the pellet resuspended in 100ml HAT selection medium. A 100µl of fused 
cells were dispensed per well in 10 x 96well/plates and feed with another 100µl/well 
HAT medium immediately or the next day for a final volume of 200µl/well. On day 3, 5 
and 7 after the fusion a 100µl of medium was removed from each well and replaced with 
100µl HAT selection medium. Some wells were be ready by day 10, the majority cells 
were screened by day 14 after the fusion.  
 
Following the generation of clonally diluted NS1 hybridomas, the supernatants of each 
hybridoma were screened by enzyme linked immunofluorescent assay (ELISA). A 
control Fc-hDectin-1 protein was provided by Dr. J Willment (UCT) (this soluble protein 
is designed similarly to Fc-hCLEC9A) and Fc-hCLEC9A soluble protein was coated on 
the ELISA plates at 1μg/ml overnight at 4˚C. The plates were then washed with PBS-
Tween 0.5% and blocked with 0.5% BSA at 37˚C for 2 hours. After washing, 50μl 
hybridoma supernatant was added and incubated at 37˚C for 2 hours before washing and 
then detection with an alkaline phosphatase conjugated anti-murine secondary antibody 
(from Jackson).  
 
2.4.4 Western blotting and deglycosylation 
To prepare cellular extracts, cells were washed with PBS and then lysed in cell lysis 
buffer (CLB), supplemented with protease inhibitors (from Roche), for 30 minutes at 
4°C. Cellular debris/nuclei were removed by centrifugation, and supernatants were 
collected and stored at -20°C. Protein concentrations of cell extracts were determined by 











according to standard protocols. After transfer to HybondC+ nitrocellulose membranes 
(from Amersham), CLEC9A was detected by immunostaining with 9A11 or anti-HA 
(clone 16B12, from Covance) followed by goat anti-mouse HRP (from Jackson). Blots 
were developed with the ECL-plus kit (from Amersham).  
 
NIH3T3 transfected fibroblasts were lysed in CLB, supplemented with protease 
inhibitors, for 30 minutes at 4°C. Cellular debris/nuclei were removed by centrifugation, 
and supernatants were collected and deglycosylated with PNase F and/or O-glycosidase 
(from Roche), as described by the manufacturer. 
 
2.4.5 Cell sorting 
The following antibodies were used in these experiments: 9A11-biotin, D1.3-biotin (a 
gift from Dr L. Martinez-Pomares, Oxford University), CD1a, CD2, CD3-  fluorescein 
isothiocyanate (FITC) (Serotec), CD4-phycoerythrin (PE) (Serotec), CD8-PE (Serotec), 
CD11b-FITC (Serotec), CD11c-FITC (Serotec), CD14-FITC (BD-Pharmingen), CD16-
PE (BD Pharmingen), CD19-PE (BD-Pharmingen), CD56-PE (BD-Pharmingen), CD83-
PE (Serotec), CD86-PE (Serotec), BDCA-1-FITC (BD Pharmingen), BDCA-2-PE (BD 
Pharmingen), DC-SIGN-FITC (BD Pharmingen), HLA-DR-FITC (BD Pharmingen), 
BDCA3-PE (Miltenyi)  and irrelevant biotin-, PE- or FITC-labeled mouse IgG1 (D1.3) 
IgG2a (BD Pharmingen) and IgG2b (BD Pharmingen) control antibodies. Biotinylated 












To isolate 9A11+ cells for analysis, 30 million PBMCs, isolated as described above, were 
blocked with 5% mouse serum or 50μg/ml human IgG for 15 minutes at 4ºC. Cells were 
then stained with biotinylated 9A11 mAb for 30 minutes at 4ºC, followed by streptavidin-
APC (BD Pharmingen), and APC+ cells were sorted using FACSVantage SE (Beckton 
Dickinson). The sorted cells were kept at 4˚C throughout the sorting procedure and then 
stained for various surface markers, as described above.  
 
2.4.6 Immunostaining of NIH3T3 cells 
Immunohistochemistry was performed to test the monoclonal antibody specificity on 
transfected NIH3T3 cells. Cells were plated on coverslips, which had been placed in 6 
well plates (2x105 per well). The cells were fixed at RT in 2% paraformaledehyde (4% 
paraformaldehyde, 250mM HEPES, 6ml dH2O) for 20 minutes and quenched for 10 
minutes at RT. Cells were permeabilized in 0.5% Triton X-100 (from Sigma) for 20 
minutes at RT, washed three times with 0.1% PBS-Tween and blocked FACS block 
containing 0.5% saponin. The cells were stained with anti-HA.11 and/or 9A11 at 
10μg/ml for 1 hour at RT and subsequently washed with 0.1% PBS-Tween to remove all 
unbound antibody. Cells were stained with donkey anti-mouse Cy3 (1/100 dilution, from 
Jackon) for 1 hour at RT and subsequently washed with 0.1% PBS-Tween. The cell 
nuclei were detected with DAPI (1:10,000 dilution, from Sigma). Coverslips were 
mounted with Vectashield (from Vector laboratories) and examined by conventional 
fluorescence microscopy on a Zeiss Axiovert 40. Images were processed using Adobe 












2.4.7 Endocytosis assays 
For the endocytosis assays, transduced NIH3T3 or RAW264.7 cells were plated at 4x105 
cells/well and 5x105 cells/well respectively, in 6 well plates the day before the 
experiment. At the start of the assay, cells were washed and then incubated in FACS 
block for 30 minutes at 4°C. Cells were stained with biotinylated 9A11 or anti-mDectin-1 
(2A11; 10μg/ml) and incubated for 50 minutes at 4°C and subsequently washed with 
FACS wash, to remove unbound antibody. A cross-linking sheep anti-mouse antibody 
(5μg/ml, from Jackson) was added and the cells incubated for a further 30 min at 4°C. 
After washing in culture medium to remove unbound secondary antibody and azide, the 
cells were incubated in culture medium for the times indicated at either 37°C or 4°C. 
Cells were then stained with streptavidin-PE (from BD Pharmingen), and examined for 
remaining receptor surface expression by flow cytometery, as described above.  
 
For microscopy, cells were plated at 2x105/well on glass coverslips in 6-well plates the 
day before the experiment. Cells were treated the same as for the FACS based assay, only 
stained with 9A11 for 1 hour at 4°C and subsequently washed with FACS wash to 
remove unbound antibody. Cells were incubated for 30 minutes at either 37°C or 4°C in 
culture medium. After incubation the cells were fixed in 1ml fixative (4% 
paraformaldehyde; 250mM HEPES in dH2O) for 20 minutes. The aldehyde groups were 
quenched with PBS Glycine (25mM Glycine powder in PBS) for 10 minutes and cells 
were permeabilized with 0.5% Triton X-100 for 20 minutes. Cells were washed with 
0.1% PBS-Tween and permeabilised thereafter with 0.5% Saponin for 20 minutes. Cells 











University of Iowa, Iowa City) for 1 hour at RT and washed with 0.1% PBS-Tween. 
Cells were then stained with donkey anti-mouse Cy3 and donkey anti-rat Alexa488 
(1/100 dilution; both from Jackson) for 50 minutes at RT and subsequently washed with 
0.1% PBS-Tween. Coverslips were mounted with Vectashield and examined by 
conventional fluorescence microscopy on a Zeiss Axiovert 40. Images were processed 
using Adobe Photoshop version 6.0. 
  
2.4.8 Phagocytosis assays 
To quantify phagocytosis by flow cytometry, transduced NIH3T3 fibroblasts or 
RAW264.7 macrophages were seeded at 2x105cells/ well in 6 well plates the day before 
the experiment. When required, cells were pre-treated with 5μM cytochalasin D (from 
Calbiochem) for 40 min at 37˚C, to inhibit phagocytosis. Cells were then washed and 
FITC-labeled zymosan was added (1 particle/ cell) and allowed to bind for 1 hr at 4˚C. 
Unbound zymosan was removed by washing and the cells incubated at 37˚C for 2 hours 
(NIH3T3 cells) or 30 min (RAW264.7 cells) to allow particle uptake. The amount of 
internalized zymosan was then determined by flow cytometery, as previously described 
[51]. Briefly, external zymosan was stained with polyclonal rabbit anti-zymosan (from 
Invitrogen), which was subsequently detected with APC-labeled goat anti-rabbit antibody 
(from Invitrogen). Flow cytometeric analyses were performed by gating on the FITC-
positive cell populations, which had bound zymosan, and the percentage of 
internalization was determined by comparing the APC-negative (internalized particles) 
versus the APC-positive (non-internalized particles) cell populations. The examination of 











transduced cells were seeded at 3x104 cells/ well on glass coverslips, 10 particles per cell 
of FITC-labeled zymosan were added, and the cells were allowed to internalize the 
particles for 45 min at 37˚C. Following this incubation, the cells were washed, fixed with 
4% paraformaldehyde and permeabilised with 0.05% saponin in FACS block for 30 min 
at RT. Actin was stained with 1μM tetramethylrhodamine isothiocyanate (TRITC)-
labeled phalloidin (from Sigma). Coverslips were mounted with Vectashield and 
examined by conventional fluorescence microscopy on a Zeiss Axiovert 40. Images were 
processed using Adobe Photoshop version 6.0. 
 
2.4.9 Zymosan binding and cytokine assays 
RAW264.7 and NIH3T3 transfectants were plated at 5x104 cells/well in 24-well plates 
the day before the experiment. Cells were washed, soluble β-glucans (glucan phosphate; a 
kind gift from Dr. D. Williams, ETSU; 5μg/ml) added where appropriate, and the cells 
incubated for 20 minutes at 4˚C to allow inhibition of the Dectin-1 CRD [29]. Following 
the addition of FITC-labeled zymosan (25 particles/cell, from Invitrogen), cells were 
incubated at 4˚C for 60 minutes to allow binding, and then washed extensively to remove 
unbound particles. For the determination of TNF-α production, RAW264.7 cells were 
incubated for a further 3 hr and the amount of TNF-α released into the supernatants was 
determined by ELISA (from BD Biosciences). For measuring zymosan binding, cells 
were lysed in 3% Triton X-100 and the amount of bound zymosan was quantified by 












For the analysis of the Syk-sufficient and Syk-deficient B-cells, 2x106 transduced cells 
were stimulated with unlabelled zymosan (1 particle per cell, from Sigma) in 24 well 
suspension plates for 24 hours at 37˚C. IL-2 secreted into the supernatants was quantified 
by ELISA (from BD Biosciences). Where indicated, piceatennol (from Sigma) was 
included at 50µM.  
 
2.4.10 Immunoprecipitations 
1x107 RAW264.7 cells were stimulated with pervanadate for 1 min at 37ºC, and the cells 
lysed in ice-cold lysis buffer with protease inhibitors (from Roche). Nuclei and cell debris 
were removed by centrifugation, and the recovered supernatants were added to 
streptavidin beads (from Sigma), pre-coupled with biotinylated phosphorylated or 
unphosphorylated peptides (25μM). The CLEC9A peptides were generated commercially 
(from Sigma) and corresponded to the following region of the cytoplasmic tail of the 
receptor, 1MHEEEIYRSLQWD13. The Dectin-1 peptides have been described previously 
[120]. The beads were rotated for 2 hr at 4ºC and then washed, prior to analysis by 
Western blotting. Proteins in the immunoprecipitates were detected with anti-
phosphotyrosine (clo e 4G10), anti-Syk and anti-Lyn (from Santa Cruz), followed by 
appropriate HRP-linked secondary antibodies (from Jackson). 
 
2.4.11 Reporter cells 
Dr. E. Pyz (UCT) generated all the reporter chimeras consisting of the extracellular and 











CD3ξ chain were generated by PCR and cloned in the pMX-IP retroviral vector (a gift 
form Dr. T Kitamura, University of Tokyo, [186]) using the following primers: 
 
 
All constructs were verified by sequencing, packaged into virons using HEK293T-based 
Phoenix ecotropic cells, described previously [74], and used to transduce BWZ.36 
NFAT-LacZ cells.  
 
2.4.12 Endogenous and exogenous ligand screen 
C57/BL6 mice were obtained from the animal unit at the University of Cape Town. All 
animals were maintained under specific pathogen-free conditions and used at 6-10 weeks 
of age. All procedures were performed in accordance with ethical guidelines established 
by the University of Cape Town. 
 
For single cell suspensions, mouse organs were removed aseptically and disaggregated by 
maceration and strained through a 70μm cell filter. The cell suspension was washed twice 
and resuspended in culture medium. All steps were performed at 4°C. 
 
 Forward primer Reverse primer 
mDectin-1 5’CCAACTAGTCCTTGGAGGCCCATTGCAGTGG3’ 5’TTTGCGGCCGCTTACAGTTCCTTCTCACAGAT3’ 
mCLEC9A 5’AAAACTAGTGGAGCATGGTGTGTTGTGACG3’ 5’AAAGCGGCCGCTCAGATGCAGGATCCAAAT3’ 











For endogenous ligand screening, 1x105 reporter cells were co-cultured with 1x106 
isolated mouse primary cells, for 20 hours in 48 well plates. For antibody cross-linking, 
24 well plates were pre-coated with sheep anti-mouse IgG (50μg/ml) and followed by 
isotype or anti-mCLEC9A polyclonal antibody (10μg/ml). Following stimulation, IL-2 
released into the supernatants was quantified by ELISA (from BD Pharmingen), and/or 
cells were stained for β-galactosidase expression. 
 
For exogenous ligand screening, 1x105 reporter cells were co-cultured with various heat-
killed pathogens, for 20 hours in 48 well plates. Following stimulation, IL-2 released into 




Mouse organs were collected, embedded and sectioned by Dr. V Tsoni (UCT).  
Cryosections were cut 5 to 10μm thick and placed on APES (from B&M Scientific) 
coated slides and stored at -20°C.  Sections were left on the bench to reach RT and air 
dried before staining, this way the morphology is better preserved. The sections were 
washed with PBS, fixed in 4% paraformaldehyde for 10 minutes at RT and air dried 
before blocking in FACS block for 15 minutes at RT. Following the blocking step, 
sections were covered with 10μg/ml Fc-mCLEC9A and Fc-mCLEC12B and incubated at 
RT for 1 hour. Subsequently the sections were washed with PBS and stained with anti-
human Cy3 (1/100 dilution, from Jackson) in the dark at RT for 30 minutes. The sections 











detected with DAPI. Coverslips were mounted with Vectashield and examined by 
conventional fluorescence microscopy on a Zeiss Axiovert 40. Images were processed 



































Identification and in silico analysis 
 
3.1 Identification of CLEC9A 
Previous studies in our laboratory on the characterization of a CTLR called MICL led to 
the identification of a closely related receptor CLEC9A (accession number AY358265) 
based on sequence similarity and its genomic position [171]. The aim was to characterize 
this novel CTLR and determine the physiological role that it plays in the immune system.  
 
In silico based analyses are often considered as the first step in the prediction of protein 
structure and function [187, 188]. The advances in computational methodologies have 
enhanced the comprehensive description of structural and functional domains or 
conserved motifs. Utilizing these computational assays has revealed several key features 
of the group V ‘Dectin-1 cluster’ of CTLRs. For example, all of these receptors consist of 
a single ‘non-classical’ CTLD, lacking the residues involved in Ca2+ -dependent binding; 
some contain cysteine residues in their stalk region essential for dimerization [12]; the 
cytoplasmic tail contain various conserved signaling motifs including ITAM-like [51, 
101]  and ITIMs [171, 179]; several other group V CTLRs also contain tri-acidic 
internalization motifs [33, 46].  
 
This chapter describes the computational analysis of CLEC9A sequences used to analyze 
the primary and secondary structural components of this receptor, analyzing the 











and determining possible functional similarities shared between related C-type lectins 
that are part of the ‘Dectin-1 cluster. These in silico driven experiments revealed several 
features of CLEC9A, which will be discussed in this chapter.  
 
3.2    Results 
 
3.2.1 Sequence analysis and genomic structure of CLEC9A 
The human clec9A gene is located on the plus strand of human chromosome 12 (locus 
12p13) within the NKC, spanning approximately 13kb of genomic DNA (Figure 1.4). 
hclec9A consists of six exons, containing a single predicted open reading frame (ORF) 
encoding a protein of 241 amino acids with a predicted molecular mass of ~30kDa 
(Figure 3.1 A). The hclec9A gene is predicted to encode a type II transmembrane protein 
with a single extracellular CTLD, a stalk region and a cytoplasmic tail with a potential 
signaling motif (YxxL) [124] (Figure 3.1 B). The CTLD of hCLEC9A contains the six 
conserved cysteine residues likely to be involved in disulfide bond formation and 
stabilization of the CTLD fold [14], a typical feature of the group V CTLRs and lacks the 
residues involved in Ca2+-dependend binding in classical C-type lectins [12]. This implies 
that hCLEC9A is part of the ‘non-classical’ CTLRs.  
 
The transmembrane domain of human and murine hCLEC9A was characterized by 
submitting their amino acid sequences to the online database Pfam (Protein family 
database of alignments and HMMs)e and DNAMAN hydrophobicity plots (Figure 3.2 A).  
 
                                                 






































Fig. 3.1 Human CLEC9A gene structure and encoded polypeptide sequence. A)
Schematic representation of  the genomic structure of CLEC9A aligned with the encoded 
polypeptide, showing the positions of the exons in the genomic DNA (gDNA) and 
corresponding translated amino acid sequence. B) The nucleotide and translated protein 
sequence of CLEC9A. The putative ITAM-like motif is boxed; the transmembrane region 
is underlined by a double solid line; and the stalk region is underlined by a dashed line. 
The two cysteine residues in the stalk region are boxed and the six conserved cysteine 
residues in the CTLD are in bold and underlined. A putative N-glycosylation site is 
highlighted in grey. The black arrows (▼) indicate the exon boundaries of CLEC9A. C)
Cartoon structure of predicted human CLEC9A (S: cysteine residue; Y: tyrosine residue; 
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1 30 31 57 58 106 107 157 158 198 199 241
1   ATGCACGAGGAAGAAATATACACCTCTCTTCAGTGGGATAGCCCAGCACCAGACACTTAC 
1    M  H  E  E  E  I  Y  T  S  L  Q  W  D  S  P  A  P  D  T  Y   
                                 ▼ 
61  CAGAAATGTCTGTCTTCCAACAAATGTTCAGGAGCATGCTGTCTTGTGATGGTGATTTCA 
21   Q  K  C  L  S  S  N  K  C  S  G  A  C  C  L  V  M  V  I  S   
                                                        ▼ 
121 TGTGTTTTCTGCATGGGATTATTAACAGCATCCATTTTCTTGGGCGTCAAGTTGTTGCAG 
41   C  V  F  C  M  G  L  L  T  A  S  I  F  L  G  V  K  L  L  Q   
 
181 GTGTCCACCATTGCGATGCAGCAGCAAGAAAAACTCATCCAACAAGAGAGGGCACTGCTA 
61   V  S  T  I  A  M  Q  Q  Q  E  K  L  I  Q  Q  E  R  A  L  L   
 
241 AACTTTACAGAATGGAAGAGAAGCTGTGCCCTTCAGATGAAATATTGCCAAGCCTTCATG 
81   N  F  T  E  W  K  R  S  C  A  L  Q  M  K  Y  C  Q  A  F  M   
                    ▼ 
301 CAAAACTCATTAAGTTCAGCCCATAACAGCAGTCCTTGTCCAAACAATTGGATTCAGAAC 
101  Q  N  S  L  S  S  A  H  N  S  S  P  C  P  N  N  W  I  Q  N   
 
361 AGAGAAAGTTGTTACTATGTCTCTGAAATTTGGAGCATTTGGCACACCAGTCAAGAGAAT 
121  R  E  S  C  Y  Y  V  S  E  I  W  S  I  W  H  T  S  Q  E  N   
                                                       ▼ 
421 TGTTTAAAGGAAGGTTCCACGCTGCTACAAATAGAGAGCAAAGAAGAAATGGATTTTATC 
141  C  L  K  E  G  S  T  L  L  Q  I  E  S  K  E  E  M  D  F  I   
 
481 ACTGGCAGCTTGAGGAAGATTAAAGGAAGCTATGATTACTGGGTGGGGTTGTCTCAGGAT 
161  T  G  S  L  R  K  I  K  G  S  Y  D  Y  W  V  G  L  S  Q  D   
                                                           ▼ 
541 GGACACAGCGGACGCTGGCTTTGGCAAGATGGCTCCTCTCCTTCTCCTGGCCTGTTGCCA 
181  G  H  S  G  R  W  L  W  Q  D  G  S  S  P  S  P  G  L  L  P   
 
601 GCAGAGAGATCCCAGTCAGCTAACCAAGTCTGTGGATACGTGAAAAGCAATTCCCTTCTT 
201  A  E  R  S  Q  S  A  N  Q  V  C  G  Y  V  K  S  N  S  L  L   
 
661 TCGTCTAACTGCAGCACGTGGAAGTATTTTATCTGTGAGAAGTATGCGTTGAGATCCTCT 
221  S  S  N  C  S  T  W  K  Y  F  I  C  E  K  Y  A  L  R  S  S   
  
721 GTCTGA 
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Fig. 3.2 Transmembrane and N-glycosylation predictions for CLEC9A. A) 
Hydrophobicity plots of human and murine CLEC9A. The red bars indicate the predicted 
amino acid position of the transmembrane domains. B) The putative N-glycosylation 
sites were predicted by using the online database NetNGlyc 1.0. Positive sites were 














N- and O-glycosylation sites were predicted by using the online database NetNGlyc 1.0 
and NetOGlycf. hCLEC9A consists of a single predicted N-linked glycosylation site 
(Figure 3.2 B), there were no predictions observed for any O-linked glycosylation sites, 
and possesses two cysteine residues in the stalk region, which may potentially lead to the 
dimerization of this molecule [12] (Figure 3.1 C). Additionally, hclec9A contains a 
putative internalization motif (tri-acidic sequence: EEE) in its cytoplasmic tail, indicating 
that this receptor may function as a potential endocytic receptor [33] (Figure 3.1 B).  
 
The murine orthologue of human CLEC9A was identified based on its shared homology 
using the online database BLASTe and the genomic position. Sequence analysis indicates 
that the murine clec9A gene (accession number AK041288), like the human orthologue, 
encodes a type II transmembrane protein of 238 amino acids with a predicted molecular 
weight of ~30kDa (Figure 3.3 A). Similar to the human gene, mclec9A consists of six 
exons according to GenBank TM/EBI contig NT_039356 and is located on the plus 
strand of chromosome 6. The mCLEC9A retains most of the structural features as 
described for hCLEC9A, including the intracellular signaling motif (YxxL) (Figure 3.2 
B). However, from the deduced amino acid sequence, the murine receptor appears to 
have an additional N-glycosylation site in its CTLD and lacks one of the cysteine 







                                                 
f see website http:cbs.dtu.dk/services/NetNGlyc/ and /NetOGlyc/). 



































1   ATGCATGCGGAAGAAATATATACCTCTCTTCAGTGGGACATTCCTACCTCAGAGGCCTCT 
1    M  H  A  E  E  I  Y  T  S  L  Q  W  D  I  P  T  S  E  A  S  
                                      ▼ 
61  CAGAAGTGCCAATCCCCTAGCAAATGTTCAGGAGCATGGTGTGTTGTGACGATGATTTCC 
21   Q  K  C  Q  S  P  S  K  C  S  G  A  W  C  V  V  T  M  I  S   
                                                        ▼ 
121 TGTGTGGTCTGTATGGGCTTGTTAGCAACGTCCATTTTCTTGGGCATCAAGTTCTTCCAG 
41   C  V  V  C  M  G  L  L  A  T  S  I  F  L  G  I  K  F  F  Q   
 
181 GTATCCTCTCTTGTCTTGGAGCAGCAGGAAAGACTCATCCAACAGGACACAGCATTGGTG 
61   V  S  S  L  V  L  E  Q  Q  E  R  L  I  Q  Q  D  T  A  L  V   
 
241 AACCTTACACAGTGGCAGAGGAAATACACGCTGGAATACTGCCAAGCCTTACTGCAGAGA 
81   N  L  T  Q  W  Q  R  K  Y  T  L  E  Y  C  Q  A  L  L  Q  R   
                 ▼ 
301 TCTCTCCATTCAGGTAGTGACTGCAGCCCTTGTCCACACAACTGGATTCAGAATGGAAAA 
101  S  L  H  S  G  S  D  C  S  P  C  P  H  N  W  I  Q  N  G  K   
 
361 AGTTGTTACTATGTCTTTGAACGCTGGGAAATGTGGAACATCAGTAAGAAGAGCTGTTTA 
121  S  C  Y  Y  V  F  E  R  W  E  M  W  N  I  S  K  K  S  C  L   
                                                 ▼ 
421 AAAGAGGGCGCTAGTCTCTTTCAAATAGACAGCAAAGAAGAAATGGAGTTCATCAGCAGT 
141  K  E  G  A  S  L  F  Q  I  D  S  K  E  E  M  E  F  I  S  S   
 
481 ATAGGGAAACTCAAAGGAGGAAATAAATATTGGGTGGGAGTGTTTCAAGATGGAATCAGT 
161  I  G  K  L  K  G  G  N  K  Y  W  V  G  V  F  Q  D  G  I  S   
                                                ▼ 
541 GGATCTTGGTTCTGGGAAGATGGCTCTTCTCCTCTCTCTGACTTGTTGCCAGCAGAAAGA 
181  G  S  W  F  W  E  D  G  S  S  P  L  S  D  L  L  P  A  E  R   
 
601 CAGCGATCAGCCGGCCAGATCTGTGGATACCTCAAAGATTCTACTCT ATCTCAGATAAG 
201  Q  R  S  A  G  Q  I  C  G  Y  L  K  D  S  T  L  I  S  D  K   
 
661 TGCGATAGCTGGAAATATTTTATCTGTGAGAAGAAGGCATTTGGATCCTGCATCTGA 
221  C  D  S  W  K  Y  F  I  C  E  K  K  A  F  G  S  C  I  *   
B
Y
Fig. 3.3 Murine CLEC9A gene structure. A) The nucleotide and translated protein 
sequence of murine CLEC9A. The putative signaling motif is boxed; the transmembrane 
region is underlined by a double solid line; and the stalk region is underlined by a dashed 
line. The single cysteine residue in the stalk region is boxed and the conserved cysteine 
residues in the CTLD are in bold and underlined. The black arrows (▼) indicate the exon
boundaries of mCLEC9A. B) Cartoon structure of the predicted mCLEC9A receptor (Y: 
















3.2.2 Homologies with other species and known C-type lectins 
 
The predicted hCLEC9A amino acid sequence was used to identify its closest 
homologues by searching various on-line databasesg. As indicated by sequence analysis  
mCLEC9A is 53% identical to hCLEC9A, and retains most of the structural features 
described previously, including the potential intracellular signaling motif [124] (Figure 
3.4). CLEC9A-related gene sequences were found in other vertebrate genomes, including 
Macaca mulatta, Canis familiaris, Bos taurus and Rattus norvegicus (Figure 3.5). There 
is a 77.94% similarity shared between the protein sequences of the different CLEC9A 
species. The six conserved cysteine residues in the CTLD, the signaling motif in the 
cytoplasmic tail and one of the predicted N-linked glycosylation sites were retained 
among all gene sequences as indicated in Figure 3.5. All the CLEC9A-related genes had 
only a single cysteine residue present in the stalk region, except for the human gene, 
which possesses two (Figure 3.5).  
 
Previously published analysis suggests that the CTLD of CLEC9A is closely related to 
the one found in the killer-lectin receptor 1 (KLR-I) [189]. Our analysis, using NCBI 
Blast protein analysisg, shows that despite having a high degree of similarity to KLR-I 
and some members of the KLR complex, hCLEC9A is phylogenetically most related to 
MICL (CLEC12A) and CLEC12B, whereas the mCLEC9A shares most sequence 
similarity with mDectin-1 (CLEC7A) as well as mCLEC12B. Thus CLEC9A is mostly 
homologous to other C-type lectin-like molecules found on the ‘Dectin-1 cluster’ of 
CTLRs (Figure 3.6 A).  




































 hCLEC9A  MHEEEIYTSLQWDSPAPDTYQKCLSSNKCSGACCLVMVIS   40
 mCLEC9A MHAEEIYTSLQWDIPTSEASQKCQSPSKCSGAWCVVTMIS   40 
  
 hCLEC9A CVFCMGLLTASIFLGVKLLQVSTIAMQQQEKLIQQERALL   80 
 mCLEC9A CVVCMGLLATSIFLGIKFFQVSSLVLEQQERLIQQDTALV   80 
 
 hCLEC9A NFTEWKRSCALQMKYCQAFMQNSLSSAHNSSPCPNNWIQN  120 
 mCLEC9A NLTQWQR..KYTLEYCQALLQRSLHSGSDCSPCPHNWIQN  118 
 
 hCLEC9A RESCYYVSEIWSIWHTSQENCLKEGSTLLQIESKEEMDFI  160 
 mCLEC9A GKSCYYVFERWEMWNISKKSCLKEGASLFQIDSKEEMEFI  158 
 
 hCLEC9A TGSLRKIKGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLP  200 
 mCLEC9A S.SIGKLKGGNKYWVGVFQDGISGSWFWEDGSSPLSDLLP  197 
 
 hCLEC9A AERSQSANQVCGYVKSNSLLSSNCSTWKYFICEKYALRSSV 241 
 mCLEC9A AERQRSAGQICGYLKDSTLISDKCDSWKYFICEKKAFGSCI 238 
 
Fig. 3.4 Sequence homology between human and murine CLEC9A. Comparison of 
the human and murine CLEC9A polypeptide sequences. Light gray highlights indicate 
identity and dark gray highlights indicates similarity. The signaling motif in the 
cytoplasmic tail is boxed (YxxL). The missing cysteine in the stalk region of mCLEC9A 



































Fig. 3.5 Homology shared between CLEC9A related genes sequences found in other 
vertebrate genomes. The full length CLEC9A protein sequences from Homo sapiens, Macaca 
mulatta, Canis familiaris, Bos taurus, Mus musculus and Rattus norvegicus share 77.94% 
identity. Homology is indicated by dark gray (100%) and light gray (>75%). The signaling motif 
in the cytoplasmic tail  (ExYxxL) is retained and conserved between species as indicated by the 
black arrows (▼). The conserved six cysteine residues involved in the CTLD fold are indicated 
by the asteriks (*). The extra cysteine residue in the stalk region of hCLEC9A is indicated by (#) 
and the predicted N-glycosylation sites are boxed (NF/LT).
Homo sapiens      MHEEEIYTSLQWDSPAPDTYQKCLSSNKCSGACCLVMVIS     40 
Macaca mulatta    MHEEEIYTSLQWDSPAPnTYQKCLSSNKCSGAwCLVMaIS     40 
Bos Taurus        MqEdEIYTSLQWDtPtsnpYQKhLSStKnSGvwCLVMVIl     40 
Canis familiaris  MqEEEtYTSLrWDSPtPsfYQKhLSStKySGAwCLVtVIt     40 
Rattus norvegicus MHEEEIYTSLQWDiPtseasQKCpSlsKCpGtwCiVtVIS     40 
Mus musculus      MHaEEIYTSLQWDiPtseasQKCqSpsKCSGAwCvVtmIS     40 
 
Homo sapiens      CVFCMGLLTASIFLGVKLLQVSTIAMQQQEKLIQQERALL     80 
Macaca mulatta    CiFCMGLLTASIFLGVKLLQVSTIAMQQQEKLIQQERALL     80 
Bos taurus        CiFCiGsLatSIFLGiKLfQmSTtiMkQQEKLIQQERALL     80 
Canis familiaris  CilCvGsiatSvFLGlKLfQVSTIAMkQrEKLIlQdRALL     80 
Rattus_norvegicus CVvCvGLLaASIFLGiKfsQVSslvMeQrErLIrQdtALL     80 
Mus musculus      CVvCMGLLatSIFLGiKffQVSslvleQQErLIQQdtALv     80 
 
Homo sapiens      NFTEWKRSCALQMKYCQAFMQNSLSSAHNSSPCPNNWIQN    120 
Macaca mulatta    NFTEWKRShvLQMKfCQtFMQsSfSSAHNcSPCPNNWIQN    120 
Bos Taurus        NFTqWKRnpnLQMtYCQtlMQkSLSSAyNcSPCPdNWIQN    120 
Canis familiaris  NFTqWeRnhnLQMKYCQtlMQNSfSSAHNcSPCPdNWIQN    120 
Rattus norvegicus NlTEWqRnhtLQlKsCQAslQrSLrSgsNcnPCPpNWIQN    120 
Mus musculus      NlTqWqRkytLey..CQAllQrSLhSgsdcSPCPhNWIQN    118 
 
Homo sapiens      RESCYYVSEIWSIWHTSQENCLKEGSTLLQIESKEEMDFI    160 
Macaca mulatta    RESCYYVSEhWkIWHTSQENCLKEGSTLLQIESeEEMDFI    160 
Bos taurus        gESCYhVfEsWtfWHTSrkdCwKkGSdLLQIESKEEMDFI    160 
Canis familiaris  gESCYhVfEnWkIWHTSkEdCLKEGSnLLQIdSKEEMDFI    160 
Rattus norvegicus gkSCYYafdrWetWnnSkksCLKEGdsLLQIdSKEEMeFI    160 
Mus musculus      gkSCYYVfErWemWniSkksCLKEGasLfQIdSKEEMeFI    158 
 
Homo sapiens      TGSLRKIKGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLP    200 
Macaca mulatta    TGSLRKIrGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLP    200 
Bos Taurus        TGSLkKIKrnYDYWVGLSQnGsnqpWLWQDGSSPSadLLP    200 
Canis familiaris  TGSLkKvKsgfDYWVGLSQDGlSkpWLWQDGSSPSPdLsP    200 
Rattus norvegicus nlSiwKlKGgYeYWVGvfQDGpSGsWfWeDGSSPlsdLLP    200 
Mus musculus s.SigKlKGgnkYWVGvfQDGiSGsWfWeDGSSPlsdLLP    197 
 
Homo sapiens      AERSQSANQVCGYVKSNSLLSSNCSTWKYFICEKYALRSSV    241 
Macaca mulatta    vEiSQStNQVCGYiKnsSLLSSNCSTWKYFICEKYALRSSV    241 
Bos taurus       rqgpQStNQVCGYlrdNdLsSaNCSvWKYFICEKYALRSSt    241 
Canis familiaris  vqtlQStNQlCGYlKdkfLsSaNCSiWKYFICEKYALRSSn    241 
Rattus norvegicus tdRqlSAsQiCGYlKdhtLiSdNCSnWKYFICEKkAfgSci    241 







































Fig. 3.6 Comparative homology of hCLEC9A with receptors that are part of the ‘Dectin-
1 cluster’ of CTLRs and the ITAM-bearing receptors. A) The phylogenetic tree represents 
the homology shared by the full length human protein sequences of CLEC9A and the related 
“Dectin-1 cluster’ of  CTLRs. Dectin-1 (NP_922938); CLEC-1(NP_057595 ); CLEC-2 
(NP_057593); MICL (NT_009714); CLEC12B (NP_995324) and LOX-1 (NCBI XP_149798.2). 
The values indicate percentage similarity of each CTLRs to the hCLEC9A. B) Alignment of 
the cytoplasmic tail of  CLEC9A with that of Dectin-1[50] and CLEC-2[127] showing the first 30 
residues of the ITAM-containing signaling motifs. The conserved residues of the ITAMs are 
indicated by asterisks (*); the full consensus sequence ExYxxL. Light gray indicates 100% 























hCLECA           ........MHEEEIYTSLQWDSPAPDTYQKCLSSNKCS       30 
mCLEC9A          ........MHaEEIYTSLQWDiPtseasQKCqSpsKCS       30 
Dectin-1         meyhpdlenldEdgYTqLhfDSqsntriav........       30 
CLEC-2           ........MqdEdgYitLniktrkPalvsvgpaSssww       30 
Consensus                   e  y  l 











From this alignment CLEC9A possesses a tyrosine residue in its cytoplasmic tail that 
resembles the ITAM-like motif of Dectin-1 [51] and CLEC-2 [125] (Figure 3.6 B), 
suggesting that CLEC9A may function as a potential activatory receptor. The 
cytoplasmic domain of most CTLRs is essential for their physiological role in the 
immune system [101, 103]. 
 
3.3   Discussion 
Using in silico based analysis I characterized a novel CTLR, called CLEC9A. This 
chapter describes the genomic, mRNA and predicted amino acid sequences for CLEC9A, 
including sequence based domain and motif analysis, the identification of shared 
homologues and predicted function. CLEC9A is part of the group V CTLRs, in terms of 
exon and polypeptide structures, as well as a CTLD that conforms to the basic structure 
of C-type lectins but lacks the conserved Ca2+-binding residues involved in carbohydrate 
binding (Figure 3.1 B). Subsequently two other groups (Caminschi et al. [190] and 
Sancho et al. [191]) also identified CLEC9A as a novel C-type lectin receptor, showing 
that human and murine CLEC9A genes each encode a type II transmembrane protein 
with a single extracellular CTLD lacking the Ca2+-binding residues involved in 
carbohydrate binding as well as a highly conserved tyrosine residue in the cytoplasmic 
tail. Thus their results confirm our findings. 
 
The human and murine CLEC9A sequences possess a tyrosine residue in their respective 
cytoplasmic tails within a potential signaling motif (YxxL) [124] (Figure 3.2 B). All the  











except LOX-1, that trigger downstream signaling cascades which regulate various 
functions in immune cells [78]. The tyrosine residue in the cytoplasmic tail of hCLEC9A 
resembles the ITAM-like motif of Dectin-1 [51] and CLEC-2 [125] suggesting that 
CLEC9A might function as a possible activatory receptor. The ITAM-like motif of 
Dectin-1 is capable of triggering various cellular responses including phagocytosis, 
synthesis of ROIs and cytokine production [106, 119, 120]. Recently it was shown that 
Dectin-1 can use this motif to couple Syk kinase and that agonists of Dectin-1 signaling 
through Syk promote the activation of DCs [103, 106, 120]. This suggests that CLEC9A 
has the potential to induce similar cellular responses, with regards to its putative 
activation motif that resembles the ITAM-like motif of Dectin-1. 
 
C-type lectins that contain tri-acidic internalization motifs (DEC-205, DC-SIGN, BDCA-
2, Dectin-1 and CLEC-1) target internalized antigens to the lysosomes and MHC class II+ 
late endosomes [41, 192] and function as antigen-uptake receptors [33].  Sequence 
analysis of CLEC9A shows that this receptor contains a tri-acidic motif in its cytoplasmic 
tail (Figure 3.2 B), indicating that this receptor may be able to function as an endocytic 
receptor and have the potential to act as an antigen-uptake receptor. Additionally, 
hCLEC9A possess two extra cytsteine residues in its stalk region that could allow protein 
homodi- or trimerization [12], whereas, the murine orthologue of CLEC9A show the 
presence of a single cysteine residue. These oligomers may be important for ligand 
binding. Conversely, the two other groups identified and characterized a seven exon 
version of mCLEC9A (accession AKO36399.1) encoding a protein of 264 amino acids 











transcript retains most of the structural features of the six exon mCLEC9A, there might 
be some functional differences observed between the two transcripts, which will be 
discussed in chapter 4. 
 
The CLEC9A gene is highly conserved between related gene sequences found on 
different vertebrate genomes as indicated in Figure 3.5. This suggests that the function of 
this receptor may have been retained through evolution, because of the 77.94% similarity 
shared between species as well as the conserved signaling motif in the cytoplasmic tail.   
 
In conclusion, the predictions made in this chapter confirmed that CLEC9A is a novel 
CTLRs that is part of the group V ‘Dectin-1 cluster’ and shares various structural features 
with the members of this cluster. Our predictions from this analysis are that CLEC9A 
may be expressed as a glycosylated homodimer, have the ability to function as an 
activation receptor with the additional potential to mediate endocytosis. The expression, 
regulation and function of CLEC9A will be presented in chapters 4, 5 and 6 along with 



















Characterization of CLEC9A expression 
 
4.1 Introduction 
The aim of this chapter was to characterize the protein and cellular expression of 
CLEC9A. Sequence analyses indicate that CLEC9A is most homologous to the group V 
‘Dectin-1 cluster’ of CTLRs. A characteristic feature of the group V receptors is the 
presence of cysteine residues within their stalk region, which is involved in homo- or 
hetero-dimerization (http://ctld.glycob.ox.ac.uk/). This may be a possible way to increase 
the efficiency of ligand binding [193]. hCLEC9A contains two cysteine residues in its 
stalk region, which may therefore lead to dimerization and facilitate ligand binding. 
 
Establishing the cellular distribution of a cell surface receptor is important to try and 
understand its function. Many of the ‘Dectin-1 cluster’ receptors are expressed on 
myeloid cells and/or endothelium and possess activating or inhibitory signaling motifs 
that trigger downstream signaling events that regulate the role of these cells [74, 144, 
162, 171]. Dectin-1, for example is known to be expressed on macrophages and 
neutrophils, where some of its major functions lie, including phagocytosis, the production 
of ROS and the induction of inflammatory cytokines [102, 121]. 
 
In this chapter I wanted to characterize the protein expression of CLEC9A in tissues, cell 












4.2 Results  
 
4.2.1 Analysis of CLEC9A expression at RNA level 
The first step in analyzing the expression of human CLEC9A was to probe various tissues 
for the presence of CLEC9A mRNA. The mRNA expression was examined by RT-PCR, 
using primers that specifically amplified the entire ORF of hCLEC9A from cDNA 
isolated from a variety of human tissues (Figure 4.1). hCLEC9A expression was found in 
most organs, but predominately in brain, thymus and spleen. Its expression in human 
tissues was detected as a single band at the predicted size of 0.8kb, suggesting that there 
were no alternative splice variants. A water sample was included as a negative control 
and a plasmid containing the hCLEC9A sequence (accession number AY358265) was 
used as a positive control (Figure 4.1). Additionally, using specific primers, the human 
housekeeping gene G3PDH was included as a loading control showing that the levels of 
expression between all tissues were comparable, indicating that the cDNA used was of a 
good quality (Figure 4.1 lower panel).  
 
The mRNA expression of murine CLEC9A was also examined by RT-PCR, using 
primers that specifically amplifed the entire ORF from cDNA isolated from a variety of 
mouse tissues. RT-PCR analysis revealed that mCLEC9A was detected in most tissues as 
multiple bands, which upon sequencing, were shown to be due to alternative splicing 
(Figure 4.2 A). High levels of mCLEC9A expression were observed in heart, spleen, 



















































































































Fig.4.1 Distribution of human CLEC9A transcripts and schematic representation 
of the constructs used in this study. Various human tissues were subjected to RT-
PCR using hCLEC9A specific primers (upper panel) or G3PDH primers (lower panel). A 
water control was included as a negative control and a plasmid containing the 
hCLEC9A sequence (accession number AY358265) was included as a positive control. 
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Fig. 4.2 mCLEC9A is expressed in multiple tissues as a number of alternatively spliced 
isoforms. A) RT- PCR analysis showing expression of mCLEC9A, detected as multiple
bands, in most tissues. mCLEC9A specific primers (upper panel) or G3PDH primers (lower 
panel) as well as a water control was included as a negative control. A plasmid containing the 
mCLEC9A sequence (accession number AK041288) represented the positive control. B)
Schematic representation of  the genomic structure of CLEC9A aligned with the predicted 
polypeptides, generated by alternative splicing, as indicated. The positions of the exons in the 
genomic DNA (gDNA) and corresponding translated amino acid sequence of full-length 


















































































































































































































intermediate levels in brain, lung, liver, kidney, testis and eye. The isoforms of 
mCLEC9A were predominantly present in spleen, lung and day 11 embryo. A water 
sample was included as a negative control and a plasmid containing the mCLEC9A 
sequence (accession number AK041288) represented the positive control (Figure 4.2 A 
upper panel). The murine housekeeping gene G3PDH was also included as a loading 
control, using primers specific for this gene, showing similar levels of expression in all 
tissues and indicating that the cDNA was of a good quality (Fig 4.2 A lower panel).  
 
The genomic structure of mCLEC9A aligned with the various predicted polypeptides, 
generated by alternative splicing, and the missing exons of each isoform are 
schematically represented in Figure 4.2 B.  
 
4.2.2 CLEC9A is expressed at the cell surface as a glycosylated dimer. 
To characterize the protein expression of human and murine CLEC9A, we cloned the 
full-length hCLEC9A (cDNA obtained from peripheral mononuclear cells) and 
mCLEC9A (cDNA obtained from spleen) in order to perform transfection studies. 
Receptor constructs containing a C-terminal epitope HA-tag were used initially, since 
anti-CLEC9A antibodies were not available at the time. Dectin-1 was included as a 
control because of its homology to CLEC9A, and the great amount of data that has been 
generated in our laboratory regarding its characterization and we have the necessary 





































Fig. 4.3 Schematic representation of constructs used in CLEC9A transfectants.
Cartoon structures of wild type full-length hCLEC9A, wild type full-length mCLEC9A 
and wild type full-length Dectin-1 showing a single C-type lectin-like domain (CTLD), a 
stalk region, a single transmembrane domain (TM) and a cytoplasmic tail (Cyto), 
respectively. Predicted N-glycosylation sites are indicated by lollipop structures and 

















To investigate whether CLEC9A was expressed and transported to the cell surface in 
heterologous cells, live NIH3T3 fibroblasts were retroviraly transduced with a HA-
tagged full-length human and murine CLEC9A were stained with an anti-HA antibody. 
Flow cytometry analysis indicated that both human and murine CLEC9A was expressed 
and transported to the cell surface in heterologous cells (Figure 4.4 A).  
 
Sequence analysis indicated that hCLEC9A possess two cysteine residues in its stalk 
region, which may lead to dimerization, and both human and murine CLEC9A have 
potential N-glycosylation sites (Figure 3.2 B). To confirm these predictions 
immunoprecipitations of HA-tagged CLEC9A transfected cells were analysed by 
Western blot. Probbing with anti-HA antibody under nonreduced conditions showed that 
the majority of hCLEC9A protein is expressed as a dimer with a molecular size of around 
97kDa, corresponding to twice the predicted molecular mass (Figure 4.4 B). The protein 
bands were reduced to two bands of approximately 50 and 55kDa under reduced 
conditions. 
 
This confirmed that hCLEC9A is expressed as a homodimer as it was predicted for 
sequence analysis. Western blot analysis shows that mCLEC9A was expressed as a 
monomer (Figure 4.4 B) with a MW of approximately 35kDa under nonreduced and 
reduced conditions. This may be due to the presence of only a single cysteine residue in 
the stalk region that is unable to form a disulphide bond that is required for 





































Fig. 4.4 Expression of hCLEC9A as a glycosylated dimer and mCLEC9A as a monomer.  
A) Flow cytometry of live NIH3T3 cells stably expressing HA-tagged hCLEC9A, mCLEC9A or 
mDectin-1, as indicated (grey lines), demonstrating expression of these receptors at the cell 
surface. The filled histograms indicate vector only transduced controls. B) Anti-HA Western 
blotting of lysates from these cells demonstrating that CLEC9A is expressed as a dimer of 
~100kDa under nonreducing conditions, which can be resolved to two bands of ~45 and 50kDa 
under reducing conditions. mCLEC9A is expressed as single band close to the predicted MW of
~30kD, indicating that mCLEC9 is expressed as a monomer. Treatment of the cell lysates with 
PNase, which removed N-linked glycosylation, reduced the molecular weight (MW) of the bands 
in hCLEC9a to close to that expected from the predicted amino acid sequence, indicating that 
hCLEC9A is N-glycosylated. Treatment with PNase did not alter the MW of mCLEC9A indicating 
that mCLEC9A is not N-glycosylated. The post-translational modification giving rise to the 
second band seen in these lysates, was not due to O-glycosylation, but was also seen with 
mDectin-1, which is expressed as a monomer and was included as a control for these 


































































































































expressed as a monomer (Figure 4.4 B), as expected [102]. Vector-only transfected cells 
were included as a negative control. 
 
To confirm whether the high MW of hCLEC9A under reduced conditions was due to 
glycosylation, cell lysates from NIH3T3 cells transfected with HA-tagged CLEC9A were 
N- and O- deglycosylated by treatment with PNase and O-glycosidase respectively. The 
two apparent bands were reduced to a MW of approximately 30 and 35kDa after PNase 
treatment (Figure 4.4 B), which removed N-linked glycosylation, indicating that 
hCLEC9A was glycosylated. Treatment with PNase did not alter the MW of mCLEC9A, 
indicating that mCLEC9A is not N-glycosylated. The post-translational modification 
giving rise to the second band apparent in the cell lysates of hCLEC9A was unlikely due 
to O-glycosylation, since there was no reduction in the MW after treatment with this O-
glycosidase treatment (Figure 4.4 B). The presence of a second band in these cell lysates, 
which was also observed with Dectin-1, may be due to other possible posttranslational 
modifications.  
 
4.2.3 Expression of hCLEC9A on primary cells 
The mRNA expression of hCLEC9A gave helpful clues as to the in vivo distribution of 
CLEC9A protein. However, the presence of a particular mRNA does not necessarily 
correlate with the expression of its encoded protein [194, 195]. Monoclonal antibodies 
(mAbs) are also a useful tool for expression and functional assays. Therefore, I generated 
a novel mAb to characterize the cellular distribution of hCLEC9A in more detail, which 











which was initially unsuccessful, however, the production of a novel mAb against 
mCLEC9A is currently in progress.  
 
4.2.4 The generation and testing of anti-CLEC9A antibody 
To generate a monoclonal antibody against hCLEC9A, a soluble Fc-CLEC9A fusion 
protein was generated, comprising of the CTLD of hCLEC9A fused with a human IgG1 
Fc domain, separated with a short spacer (Figure 4.5 A). The Fc domain allowed for the 
isolation of a highly purified protein by protein A affinity chromatography. The purified 
protein has a MW of approximately 40kDa under reduced conditions (Figure 4.5 B). 
There is no apparent N-glycosylation of the soluble Fc-CLEC9A protein, because the 
predicted N-glycosylation site in the stalk region was deleted upon the generation of the 
soluble Fc-protein. 
 
To generate the anti-CLEC9A antibody, mice were immunized with the purified Fc-
CLEC9A antigen and hybridomas were generated according to standard protocols (see 
Materials and Methods). The hybridoma supernatants were screened by ELISA and those 
that were positive for Fc-CLEC9A were examined for functionality in other assays. A 
similarly designed control Fc-protein (Fc-Dectin-1) was included in both ELISA and 
Western blot assays to demonstrate anti-CLEC9A ecto-domain specificity rather than 
anti-Fc specificity (Figure 4.6 A). Of the 996 supernatants tested only 11 hybridomas 
demonstrated specificity for Fc-CLEC9A. These hybridomas were expanded and clonally 
diluted. Thereafter the supernatants were analyzed again for their reactivity against 



































Fig. 4.5 Generating a soluble Fc fusion protein for CLEC9A. A) Cartoon structure of 
the CLEC9A Fc fusion protein used for the generation of a monoclonal antibody against 
CLEC9A. B) Western blot showing a titration series of Fc-CLEC9A 50, 100, 500 ng














































Fig. 4.6 Generation of mouse anti-human CLEC9A mAb. The supernatants of various 
hybridomas were screened by A) ELISA and B) Western blot under nonreduced conditions. 
Dectin-1 was included as a control to confirm hybridoma specificity for the CTLD of CLEC9A. 
9A11 and 10B1 were the two hybridomas that were consistently positive. The 1F1 hybridoma
was not functional in Western blot assays. The serum from mice before immunization (pre-
bleed) was used as a negative control and serum after immunization (polyclonal) was 








































































































































































conditions by Western blot (Figure 4.6 B). The 9 remaining hybridomas were not 
functional by Western blot. The 10B1 hybridoma tested negative by flow cytometry. The 
9A11 hybridoma was the only hybridoma that tested positive with ELISA, flow 
cytometry and Western blot, although it did not recognize hCLEC9A under reducing 
conditions. This hybridoma was clonally diluted three times and the cells expanded for 
antibody purification. 
 
To demonstrate that the purified 9A11 (IgG1) mAb generated against Fc-hCLEC9A was 
specific for detecting hCLEC9A, I utilized various hCLEC9A-containing reagents. 
NIH3T3- HA-tagged CLEC9A transduced cells, which confirmed surface expression of 
CLEC9A (as shown before in Figure 4.4A), were stained with 9A11 and tested positive 
by flow cytometry, but not the vector control cells; this reactivity was not significantly 
affected by fixation (Figure 4.7 A).  
 
Western blot analysis of lysates from NIH3T3 transfected with HA-tagged hCLEC9A, 
showed that 9A11, under nonreducing conditions, specifically recognized hCLEC9A 
(Figure 4.7 B). The range of protein sizes, resolving at 66-97 kDa, was similar to the 
results obtained previously in Figure 4.4 B. These sizes were comparable when the 
membranes were probed with an anti-HA mAb (Figure 4.7 B). As stated before the 9A11 






















































NIH 3T3 NIH 3T3
Live
B
Fig. 4.7 Confirming anti-CLEC9A mAb specificity. A) By flow cytometry, 9A11 reacted 
with live and fixed permeabilized NIH3T3- CLEC9A transduced cells (grey lines). The 
filled histograms indicate vector-only transduced controls. B) In Western blotting, under 
nonreducing conditions, 9A11 specifically recognized a range of protein sizes, resolving 
at 66-97 kDa, from lysates of NIH3T3 CLEC9A transduced cells. Anti-HA.11 staining on 
RAW 264.7- CLEC9A transduced cells was included as a positive control.















































































α-DAPI α-hCLEC9A (9A11) Merge
Fig. 4.8 Immunostainning of transduced cells with anti-CLEC9A (9A11). 
Immunohistochemistry of NIH3T3- CLEC9A transduced cells (upper lane) stained with 
9A11 (red) and nuclear staining with DAPI (blue). Vector-control cells  were included to 











Finally, 9A11 was confirmed to be specific for hCLEC9A by immunocytochemistry, in 
paraformaldehyde-fixed NIH3T3 transfectants (Figure 4.8). A vector-only control was 
included as a negative control. However, when human tissues (thymus and kidney) were 
paraformaldehyde-fixed and stained with 9A11, we did not detect hCLEC9A expression 
(data not shown) as it was expected in the PCR results where hCLEC9A mRNA was 
predominantly expressed. The reason for this could be that the protein expression of 
hCLEC9A is absent in these tissues, low cell number expressing hCLEC9A or 
undetectable by 9A11. We were unable to test any other tissues due to the difficulty in 
obtaining ethical approval for human tissue samples.  
 
4.2.5 Distribution of CLEC9A within peripheral blood 
The mRNA results showed that hCLEC9A was transcribed in peripheral blood 
leukocytes (PBLs) (Figure 4.1), indicating that hCLEC9A may be expressed in blood 
cells. As it is easier to obtain human PBLs in comparison with human tissues, I therefore 
used the 9A11 mAb to screen PBLs to characterize the cellular expression profile of 
hCLEC9A. 
 
Human PBMCs were stained with 9A11 (Figure 4.9 A), but the yield of positive cells 
was very low, approximately ~0.4% of total PBMC were 9A11 positive. Due to the low 
percentage of hCLEC9A expression on PBMCs, I subsequently resorted to sorting the 
9A11+ cells by flow cytometry in order to enrich for hCLEC9A on human peripheral 
blood. Furthermore, cDNA was made from RNA extracted from 9A11+ and 9A11- sorted 







































































Fig. 4.9 Expression of CLEC9A on BDCA3+DC and a subset of CD14+CD16-
monocytes. A) Dot plot showing SSC versus 9A11 staining of PBLs. R1 and R2 indicate 
the 9A11- and 9A11+ cell populations, respectively, isolated by cell sorting and analyzed for 
hCLEC9A expression by RT-PCR (B). PBMC cells expressing this receptor were sorted, 
prior to analysis by multicolor flow cytometery (C). Using various markers, as indicated, all 
CLEC9A+ cells (gated) were found  to be CD4+HLA-DR+CD11c+. D) Further analysis of the 
9A11+ cells indicated that the receptor was predominantly expressed on BDCA3+ dendritic 
cells, but also on a subset of CD64+CD11b+CD14+CD16- monocytes and a third population 
of CD64+CD11b+CD14-CD16- cells which were not identified further. The data shown are 






































The PCR results show that hCLEC9A is present in the 9A11+sorted cells and absent in 
the 9A11- sorted cells (Figure 4.9 B). The results confirmed that we have enriched for the 
hCLEC9A expressing cells. The hCLEC9A 9A11+ sorted cells obtained from PBMCs 
were stained with various antibodies specific for different subsets of cells to characterize 
the cells that hCLEC9A is expressed on. Single staining with selected markers showed 
that hCLEC9A+ cells expressed CD4, CD11c and HLA-DR (Figure 4.9 C) The majority 
of the hCLEC9A+ sorted cells were BDCA-3+ [196], and a subpopulation of CD11b+, 
CD64+ and CD14+ cells were also detected (Figure 4.9 C) Double staining with these 
markers revealed that hCLEC9A is expressed on three populations of cells, BDCA-3+ 
DCs, CD11b+/CD64+/CD14+/CD16- monocytes, and a CD11b+/CD64+/CD14-/CD16- 
population of cells which we were unable to identify further (Figure 4.9 D). The 
hCLEC9A+sorted cells were negative for the expression of CD1a, CD1c, CD2, CD8, 
CD34, CD123, BDCA-1, BDCA-2, DC-SIGN as well as lineage specific markers 
including CD3, CD19 and CD56 (Figure 4.10). Further analysis of PBMCs indicate that 
hCLEC9A was expressed on all BDCA-3+cells, 5% (±2%) of all CD11b+ cells, 2% (±1) 
of all CD14+ cells, and 6% (±3%) of all CD64+ cells (data not shown).  
 
Thus the expression of hCLEC9A was apparent on two distinct subpopulations of cells. 
The major population of hCLEC9A positive cells including a type II myeloid DCs [197] 
(CD1a-/CD4+/CD11c+/HLA-DR+/BDCA-3+) and the second minor population the 
“classical monocytes” [198] (CD11d+/CD14+/CD16-/CD64+) based on the FACS data 
































4.2.6 hCLEC9A expression on in vitro cultured macrophages and DCs, and tissues 
Circulating monocytes are recruited to tissues where they mature into macrophages and 
DCs [199]. Since hCLEC9A was found on myeloid type II DCs and a small subset of 
Fig. 4.10 Human CLEC9A staining on various PBMCs. Histograms show 
sorted 9A11 cells counterstained for various leukocytes, T-cells, B cells, NK cells 
blood DC subset markers (grey) or isotype-matched control (black). hCLEC9A 
were absent in all of these stains. The data shown are representative of data 
obtained from at least six different donors.
































monocytes, the effects of maturation on hCLEC9A expression in peripheral blood 
monocytes was also investigated. The maturation process can be mimicked by in vitro 
culture of monocytes over several days (see Matarials and Methods). Monocytes cultured 
with GM-CSF and interleukin-4 (IL-4) induce a DC-like phenotype [200]. DCs become 
activated during infections in vivo, which trigger their migration to lymph nodes and 
enhance their maturation, an effect which can be mimicked in vitro by stimulation with 
LPS.  
 
Cultured buffy coat monocytes were analyzed by live flow cytometry with 9A11 and 
other myeloid markers to confirm their phenotype (Figure 4.11). At day 1, monocytes 
isolated from peripheral blood were positive for CD14 (Figure 4.11 1st row). DC markers 
such as DC-SIGN are downregulated on these monocytes. Upon maturation towards 
macrophages, most cells are CD14+, while DC markers such as DC-SIGN and CD86 
remain low or were downregulated (Figure 4.11 2nd and 3rd row). On the contrary, 
cultured buffy coat monocytes stimulated with GM-CSF and IL-4 showed that CD14+ 
expression was slightly downregulated after four days, while the DC marker DC-SIGN 
was significantly upregulated (Figure 4.11 4th row), indicating that these cells were 
immature myeloid dendritic cells [201]. Following LPS-induced activation of cultured 
DCs, the co-stimulatory molecule CD86 was upregulated and CD14+ expression was lost 


































However, the surface expression of hCLEC9A was absent from all in vitro cultured, 




Day 4 immature DC 
GM-CSF & IL-4
Day 8 mature DC 
GM-CSF & IL-4 & LPS




Fig. 4.11 Expression of hCLEC9A on monocyte-derived macrophages and 
DC. Live (surface only) staining by flow cytometry of monocytes (1st row), 
isolated form total peripheral blood mononuclear cells  by adherence, that were 
cultured and differentiated in vitro into macrophages (analysed after 4 days (2nd
row) or 7 days (3rd row) or, with GM-CSF and IL-4, into immature DCs (analysed
at day 4, 4th row) or mature/activated DCs (by the addition of LPS at day 6 and 
analysis at day 8, 5th row). The various markers analysed are indicated at the 
bottom of each column and their staining is represented by the filled histograms, 
unfilled histograms represent staining with isotype-matched control antibodies. 
The classical markers of monocytes/macrophages/DCs behaved as expected 
and confirm the different phenotypes of the cells, while the hCLEC9A was 
absent on in vitro cultured monocytes, macrophages and DCs. Each experiment 














controls for each antibody used were also included. Thus hCLEC9A is not expressed on 
in vitro cultured macrophages and DCs derived from peripheral blood. 
 
4.3 Discussion 
This chapter described the characterization of the expression profile of CLEC9A. The 
results showed that hCLEC9A mRNA was broadly expressed as a single transcript in 
most organs, but predominantly in the brain, thymus and spleen. This is different to the 
mCLEC9A, which encodes at least five isoforms, but was also broadly expressed in most 
organs, including heart, spleen, skeletal muscle and day 11 embryo. Human Dectin-1 has 
two major isoforms and six minor isoforms, the two major isoforms are the only isoforms 
functional for binding β-glucans [74, 100]. However, these two major isoforms are 
differently expressed in various cell types, indicating that the alternative splicing of these 
specific isoforms can be regulated [74]. The physiological function and cellular 
distribution of these mCLEC9A isoforms still needs to be determined. Both human and 
murine CLEC9A were expressed and transported to the cell surface. hCLEC9A was 
expressed as a homodimer and N-glycosylated, whereas the mCLEC9A was expressed as 
a non-glycosylated monomer. The results confirmed the predictions made in chapter 3, 
which predicted that hCLEC9A possesses a single predicted N-glycosylation site (81 
NFTE) in the stalk region (Figure 3.2 B). Whereas the predictions made for mCLEC9A is 
inconsistent with the result obtained, there were two predicted N-glycosylation sites for 
mCLEC9A, one in the stalk region and one in the CTLD (Figure 3.2 B).  
As mentioned previously Sancho et al. [191] and Caminshi et al. [190], identified and 











that it is expressed as a dimer, although they did not confirm N-glycosylation. They also 
identified only three isoforms of mCLEC9A. This is in contrast to our findings, but we 
used the six exon mCLEC9A sequence for the characterization assays, which could 
explain the difference in results obtained. However all of the ‘Dectin-1 cluster’ receptors 
consist of six exons. The seven exon version of mCLEC9A contains an ‘extra’ exon in 
the CTLD (see Figure 4.2 B referred to as mCLEC9Aβ) and consists of 264 amino acids. 
This elongated version of mCLEC9A contains the residues involved for dimerization, 
which is absent in the six exon version of mCLEC9A. This is a possible explanation for 
the difference in dimerization between six and seven exon versions of mCLEC9A. 
 
To study the expression of CLEC9A in more detail we generated a novel mAb against 
hCLEC9A. The functional characterization of hCLEC9A on primary cells was limited by 
its expression on extremely rare populations of PBLs and the lack of expression on 
human tissues. Five distinct subsets of human blood DCs have been reported, including a 
population of CD123+ plasmacytoid DC (pDC) and different subsets of putatively 
myeloid CD123- DC distinguishable on the basis of expression of CD16, CD1b/c, 
BDCA-3, and CD34 [202]. The 9A11+sorted cells were negative for CD123, indicating 
that hCLEC9A is not expressed on pDC (Figure 4.10). hCLEC9A expression was also 
negative for CD34, CD16 and CD1b/c (Figure 4.10). The hCLEC9A receptor was 
predominantly expressed by BCDA-3+ DC, which represents less than 0.05% of PBMCs 
[197]. There is not much known about this cell type, although they are thought to be 
immature precursors of interstitial DCs and were recently shown to express multiple Toll-











[204], the mouse CD8α+ DCs  is known to excel in MHC class I cross-presentation of 
cell-associated foreign and self antigens [205-208]. The expression of hCLEC9A on 
BDCA3+ cells was subsequently confirmed by Sancho et al. [191]  and Caminschi et al. 
[190]. Thus hCLEC9A serves as a novel marker for BDCA-3+ cells.  
 
Caminschi et al. [190] showed that hCLEC9A was expressed on a proportion of B cells, 
whereas no expression of hCLEC9A were detected on B cells by our group or by Sancho 
et al. [191]. Their expression results of hCLEC9A on B cells were very low and they did 
not elaborate on this finding.  
 
Two major human monocyte subsets have been published, including a population of 
CD14hi, CD11bhi, CD11chi positive cells but CD2- (T cell marker), CD19-/CD24- (B cell 
marker), BDCA-2-/ CD123- (interferon producing cell marker) and CD2-/CD56- (NK cell 
marker) negative cells which correspond to the “classical monocytes”. The second 
population of monocytes are characterized as being CD14loCD16hi, CD11b+ and CD11c+ 
but negative for T, B, NK and interferon-producing cell markers corresponding to the 
CD16+ defined monocytes [209]. hCLEC9A is expressed on the “classical monocytes”, 
because the 9A11+ sorted cells were negative for CD16. CD14+/CD16- monocytes, the so-
called “classical monocytes”, which normally constitute around 14% of the PBMCs are 
thought to migrate to sites of inflammation where they can differentiate into DCs [198, 
209]. The expression of hCLEC9A on a minor subset of these cells is suggestive of 











BDCA-3+ blood DCs, and this receptor could potentially be used as a marker to 
characterize this subset in future analyses. 
 
I did not characterize the cellular distribution of mCLEC9A. However, Caminschi et al. 
[190] and Sancho et al. [191] both show that mCLEC9A was specific for mouse DCs and 
was restricted to the CD8α+ conventional DC (cDC) and at a significantly lower level on 
pDCs by antibody detection. Future RT-PCR studies should elucidate the relative 
expression profiles of the various splice variants in specific cell populations. Thus 


























5.1   Introduction 
Cell surface receptors on DCs are important for the recognition, communication, 
migration and activation of DCs. Surface molecules that vary between DC subtypes are 
of great interest, since they may support the functional specialisation of these specific 
subtypes. Surface receptors that differ between DC subtypes may identify and also serve 
as a selective delivery for antigens or therapeutic agents to DCs, in order to manipulate 
immune responses. Several antibodies against DC surface molecules, such as DEC-205, 
which have been conjugated with an adjuvant, have been used for immunotherapy of 
cancer or for boosting cellular immunity to infection [210-213]. Successful targeting 
depends on suitable DC-expressed cell surface receptors that mediate endocytosis of 
bound antibodies. This endocytic process will allow delivery of antibodies to endosomal 
compartments where their associated antigens can be processed for MHC presentation.  
Potential receptors include the MMR and Fcγ receptors that are expressed on DCs and 
other cell types. Some receptors which are more restricted to DCs include DEC-205, DC-
SIGN, Langerin, asialoglycoprotein receptor and BDCA-2 [45, 214, 215]. Most of these 
receptors belong to the C-type lectin family and may have a role in antigen-uptake, which 
could be exploited for targeting [33, 46]. 
 
Many C-type lectins act as phagocytic receptors in myeloid cells. Myeloid CTLRs often 
contain distinct internalisation motifs in their cytoplasmic tails including tri-acidic amino 
acids, di-leucine motifs and tyrosine-based motifs, which can direct both endocytosis 
and/or phagocytosis of its ligand and subsequent sorting of the receptor and its ligand 











yeast-derived particles such as zymosan, through the tri-acidic motif and the tyrosine 
residue in its cytoplasmic region, which is also required for endocytosis [51, 106, 120]. 
The intracellular pathway taken by a specific CTLR can be dependent on the receptor 
sequence motif and on the nature of the ligand [46].  For example, in DCs and fibroblasts 
expressing mDectin-1, the phagocytosis of zymosan is partly dependent on the tyrosine 
kinase Syk [106, 120]. However, in macrophages, mDectin-1 mediated phagocytosis is 
independent of Syk, yet the production of reactive oxygen species (ROS) requires this 
kinase [51, 106].  
 
The aim of this chapter is to characterize the physiological function of hCLEC9A. The 
cytoplasmic tail of hCLEC9A contains a putative internalisation motif and an ITAM-like 
motif (Figure 3.1 B) [51], which resembles the classical ITAMs that are usually 
associated with phagocytosis and activatory receptors [124]. These features make it 
possible to speculate that hCLEC9A can act as a potential endocytic receptor and/or the 
presence of an ITAM-like motif suggests that hCLEC9A is capable of mediating 
phagocytosis. Therefore we were interested whether hCLEC9A can mediate these 
processes. Signaling from the cytoplasmic tail of hCLEC9A was also investigated. The 
kinases associating with the ITAM of hCLEC9A were identified, and we determined that 
this is an activatory receptor with the ability to produce proinflammatory cytokines after 















Given the limitation in obtaining human primary CLEC9A+ cells for functional analysis, 
we resorted to determining the function of this receptor in transduced cell lines. To 
examine if hCLEC9A has the ability to mediate endocytosis, we utilized NIH3T3 
fibroblasts stably expressing hCLEC9A. Antibody mediated cross-linking of CLEC9A on 
the surface of transduced fibroblasts which were incubated at 4°C or 37°C, respectively, 
for different lengths of time before staining with a fluorescent-labeled secondary 
antibody. Flow cytometry was used to determine the surface expression of hCLEC9A. 
The surface expression of hCLEC9A was already reduced by more than 50% after 30-
minute incubation, with minimal decrease in surface expression at 4°C (Figure 5.1 A), 
indicating that the receptor was mediating internalization of the bound antibodies. Dectin-
1, which is also known to mediate endocytosis [51] was included as a positive control 
(Figure 5.1 B).  
 
In order to establish whether the observations made in the fibroblasts could be applied to 
a phagocytic cell line, the same experiment as described above was conducted in 
RAW264.7 macrophages. Similar data were obtained in transduced RAW264.7 
macrophages stably expressing hCLEC9A (Figure 5.2 B). The surface expression of 
hCLEC9A was significantly reduced following cross-linking at 37°C compared to cells 
maintained at 4°C. In order to elucidate the intracellular fate of hCLEC9A following 
















































































































0 0.5 1 21.5
Fig. 5.1 hCLEC9A is an endocytic receptor. A) Internalization of CLEC9A 
expressed in NIH3T3 fibroblasts, following antibody crosslinking, was determined by 
flow cytometry. The analysis, performed by comparing cells incubated at 37°C 
versus 4°C (to prevent internalization), demonstrates that hCLEC9A is rapidly 
removed from the cell surface following crosslinking, indicative of receptor
endocytosis. B) Dectin-1, previously shown to be endocytic[90] was included as a 
control.  The data shown are mean ± SD of triplicates, and representative of three 






















































were stained with anti-CLEC9A and co-stained with the late endosomal/lysosomal 
marker, LAMP-1, and analyzed by fluorescent microscopy.  Fluorescent microscopy of 











CLEC9A+ endocytic vesicles. Some intracellular hCLEC9A co-localized with LAMP-1 
(Figure 5.2 B) indicating that hCLEC9A could mediate delivery of bound antibody to the 
endocytic/lysosomal pathway.  
 
5.2.2   Phagocytic function of hCLEC9A 
Since the ligand for hCLEC9A is still unknown, we generated a chimeric receptor 
described in Materials and Methods, which could bind the Dectin-1 ligand, zymosan, and 
which was used to study the phagocytic ability of hCLEC9A.  This chimeric receptor 
consisted of the cytoplasmic tail, transmembrane region and part of the stalk of 
hCLEC9A fused with the CTLD of mDectin-1 (Figure 5.3 A). RAW264.7 macrophages 
stably expressing this monomeric chimera would allow us to trigger hCLEC9A signaling 
using zymosan [29]. This chimeric construct was expressed at the cell surface as well as 
the full-length hCLEC9A and mDectin-1 receptors, which were included as controls, as 
detected by flow cytometry using RAW264.7 macrophages (Figure 5.3 B). A vector-only 
cell line was included as a negative control.  
 
After confirming the cell surface expression of these transduced macrophages, we wanted 
to examine the ability of the chimera to functionally bind zymosan, using mDectin-1 as a 
positive control [29]. Cells transfected with hCLEC9A and vector only were unable to 













































comparable with that of cells expressing mDectin-1 (Figure 5.3 C). The Dectin-1 











glucan, glucan phosphate. Full-length hCLEC9A receptor does not bind zymosan (Figure 
5.3 C).  
 
Dectin-1 requires its ITAM-like motif to mediate particle uptake [51]. Therefore cells 
transfected with the chimera were used to examine their ability to internalize zymosan, 
via the cytoplasmic tail of hCLEC9A. RAW264.7 transfectants expressing the chimeric 
receptor and Dectin-1 bound zymosan equally well (Figure 5.3 C). Anti-zymosan flow 
cytometric assay show that both chimera and mDectin-1 could internalize over 65% of 
the zymosan it bound (Figure 5.4 A). Some cells were also treated with cytochalasin D to 
inhibit actin polymerisation, and prevent particle uptake, and were used as controls in 
these experiment. Furthermore, by fluorescence microscopy, FITC-labeled zymosan 
could be seen inside macrophages expressing the chimeric receptor and Dectin-1 (Figure 
5.4 C). Thus, the chimeric and Dectin-1 transfectants could mediate particle uptake in an 
actin-dependant manner in macrophages.  
 
Characterization of receptor mediated phagocytosis is generally performed in non-
myeloid cell lines to avoid confounding factors, such as antibody mediated recognition 
through macrophage Fc receptors as well as to demonstrate that the receptor can confer 
phagocytic activity in normally non-phagocytic cells. The phagocytic capacity of 
receptors, such as the Fc receptors, mannose receptor, Dectin-1 and CLECSF8 for 














































Therefore we expressed the chimeric receptor in NIH3T3 cells, which is a non-











surface expression of each construct was confirmed by flow cytometry (Figure 5.5 A). As 
before Dectin-1 was included as a positive control.  
 
The transduced-fibroblasts expressing the chimera and Dectin-1, but not vector only or 
full-length hCLEC9A, conferred the ability of these cells to bind zymosan in a β-glucan 
dependent fashion (Figure 5.5 B). Over 50% of Dectin-1 transfected fibroblasts were able 
to internalize the bound FITC-labeled zymosan, whereas the chimeric receptor was 
unable to internalize their zymosan significantly above control levels (Figure 5.5 C). As 
demonstrated by fluorescence microscopy, Dectin-1 expressing fibroblasts internalized 
FITC-labeled zymosan, while the chimeric receptor was unable to mediated particle 
uptake in these cells, as the bound FITC-labeled zymosan could not be internalized by the 
chimeric transfectants (Figure 5.5 D). Thus, hCLEC9A is not a true phagocytic receptor, 
as it is unable to mediate particle uptake in a non-phagocytic cell line. 
 
5.2.3   hCLEC9A is an activation receptor 
In addition to phagocytosis, the tyrosine-based motif of Dectin-1 can induce a variety of 
cellular responses, including the production of proinflammatory cytokines in response to 
zymosan [219]. Therefore I wanted to explore the possibility that signaling via hCLEC9A 
could induce TNF-α production in RAW264.7 macrophages transduced with the chimeric 




































































To explore the possibility that hCLEC9A can induce TNF-α production in the RAW264.7 
macrophages we utilized the chimeric receptor. The full-length hCLEC9A, vector-only 
and Dectin-1 cell lines, which were included as controls and the surface expression of 
each construct was confirmed by flow cytometry (as shown previously in Figure 5.3 B). 
As described before, expression of Dectin-1 and the chimeric receptor resulted in 
increased levels of zymosan binding in these macrophages (Figure 5.3 C). The 
transduced-macrophages were stimulated with zymosan and after three hours the 
supernatants were collected for measuring TNF-α. Dectin-1 [119] and the chimeric 
receptor resulted in high levels of TNF-α production in response to zymosan (Figure 5.6 
A). This was confirmed to be a β-glucan specific response since the response could be 
blocked by glucan phosphate (a soluble β-glucan polymer) [220]. In a previous study it 
was shown that Dectin-1 lacking a cytoplasmic tail can mediate zymosan binding but not 
the induction of TNF [119]. The results therefore indicate that the cellular response 
induced by the chimeric receptor is due to the presence of the hCLEC9A cytoplasmic tail. 
Thus, like Dectin-1, hCLEC9A signaling can induce a proinflammatory response. 
 
5.2.3.2 The kinases associated with the ITAM-like motif of hCLEC9A  
As cytokine induction mediated by Dectin-1 involves signaling via Syk [122, 219], we 
examined the possibility that this kinase was involved in the intracellular signaling 
mediated by hCLEC9A. In order to determine if Syk was recruited by the ITAM of 
hCLEC9A, tyrosine-phosphorylated and unphosphorylated peptides corresponding to the 

































































Fig. 5.6 hCLEC9A can induce pro-inflammatory cytokine production and can recruit 
and signal via Syk kinase. A) Quantitation of zymosan (zym) induced TNF production by 
transduced RAW264.7 macrophages, in the presence or absence of soluble β-glucan (β-
glu), as indicated, demonstrating the ability of the chimeric receptor to induce 
proinflammatory cytokine production. Shown are the mean ± SD of one representative 
experiment of three. *,  p < 0.05 versus control  (Student’s t test). B) Western blotting of 
immunoprecipitates using phosphorylated (pY) and unphosphorylated peptides (Y) 
corresponding to the cytoplasmic tail of CLEC9A or Dectin-1 from RAW264.7 cell lysates. 



































controls [120]. These peptides were then used to immunoprecipitate associated signaling 
molecules from RAW264.7 cell lysates, which were subsequently analyzed by Western 
blotting with specific antibodies (Figure 5.6 B). Probing with an anti-phosphotyrosine 
antibody indicated a predominant band of approximately 70kDa in immunoprecipitates 
with phosphorylated peptides of both hCLEC9A and Dectin-1. These bands were absent 
in the immunoprecipitates of unphosphorylated hCLEC9A and Dectin-1 peptides (Figure 
5.6 B). Probing with an anti-Syk antibody revealed that the one of the bands seen in the 
anti-phosphotyrosine blot was Syk with a molecular mass of 72kDa (Figure 5.6 B). 
Further blotting with various antibodies showed that hCLEC9A associated with the src 
kinase, Lyn, which is thought to be involved in tyrosine phosphorylation of ITAM motifs 
upon ligand binding [221]. These results indicate that hCLEC9A associates with Syk and 
Lyn kinases. 
 
5.2.4 hCLEC9A is Syk dependent for activation 
The results show that hCLEC9A is an activating receptor with the ability to produce pro-
inflammatory cytokines, while immunoprecipitates show that hCLEC9A associate with 
Syk. Therefore, the next step was to confirm that hCLEC9A could induce intracellular 
signaling via Syk kinase. To examine this possibility Syk-sufficient (Syk+) and Syk-
deficient (Syk-) B-cell lines were transfected with the chimeric receptor.  This approach 
was similar to that which had been used previously to demonstrate the Syk-dependent 
activity of Dectin-1 [120]. The chimeric receptor was similarly expressed at the cell 
surface of both cell types as determined by anti-2A11 flow cytometery, which detect the 


































































Fig. 5.7 hCLEC9A is Syk dependent for activation. A) Expression of the chimeric 
receptor (gray line), detected with αDectin-1, on the surface of Syk sufficient and Syk 
deficient cells, as indicated. The filled histograms indicate vector only controls. B) IL-2 
production following zymosan stimulation of Syk-deficient (Syk-) and Syk-sufficient (Syk+) 
cells, transduced with the chimeric receptor or vector only control, as indicated, showing 
that cytokine production induced by the chimeric receptor in response to zymosan requires 
Syk. The data shown are the mean ± SD and are representative of three independent 
experiments. *,  p < 0.05 versus control  (Student’s t test). C) IL-2 production following 
zymosan (zym) stimulation in the Syk+ B-cells, can be inhibited with piceatennol (pice). *,  p 

































the chimeric receptor induced significant amounts of IL-2 production (Figure 5.7 B). In 
contrast, this response was absent in vector control transduced cells and in the transduced 
Syk- cells. Furthermore, the IL-2 response could also be significantly inhibited in the 
Syk+ cells by including the Syk-inhibitor piceatannol (Figure 5.7 C). Thus, hCLEC9A 
can mediate intracellular signaling via Syk kinase.  
 
5.3 Discussion 
The chapter has described the characterization of possible functions of hCLEC9A by 
identifying elements of the cytoplamic tail. NIH3T3 fibroblasts and RAW264.7 
macrophages were transduced with the chimeric receptor (consisting of the cytoplasmic 
tail of hCLEC9A and the CTLD of Dectin-1) to probe the intracellular function of 
hCLEC9A, as a ligand for hCLEC9A was not available. A novel anti-hCLEC9A mAb 
was also used, to determine the endocytic ability of this receptor in using retrovirally 
transduced cell lines containing the full-length hCLEC9A receptor. 
 
Sequence analysis predicted that the cytoplasmic tail of hCLEC9A possesses a putative 
internalization motif. The functional characterization of this receptor revealed that 
hCLEC9A mediates endocytosis in both fibroblast and macrophage transfected cell lines. 
The results were confirmed by Sancho et al. [191]: where they show that CLEC9A 
mediates endocytosis of bound antibody in BDCA-3+ DCs, as well as endocytosis in 













The restricted expression and endocytic ability of CLEC9A suggests that this receptor 
may provide a suitable target for antibody-mediated antigen delivery to mouse CD8α+ 
DCs or human BDCA-3+ DCs, as has been demonstrated for a variety of other C-type 
lectins, including Dectin-1 [222]. Subsequently, it was shown that mCLEC9A-targeted 
antigens are efficiently cross-presented to CD8+ T cells [191], indicating that, like the 
MR and DEC205 [210, 223], CLEC9A can deliver its cargo to selected endosomal 
compartments that intersect with the MHC processing and presentation pathway. This is 
consistent with the observation that anti-CLEC9A antibody can be endocytosed by both 
human and mouse DCs and concentrate in the intracellular vesicles. 
 
Mouse CD8α+ DCs have the ability to capture material from dying cells [224, 225] and 
process these cell-associated foreign and self-antigens for MHC class I cross-presentation 
for the activation of CD8 T cells [205-208]. The activation of CD8α+ DCs leads to the 
production of IL-12 [226, 227] and are able to induce inflammatory Th1 responses [228, 
229]. Alternatively, CD8α+ DCs are also capable of effectively activating CD4 T cells 
and this feature most probably represents the role of these cells in enhancing antibody 
responses. The restricted expression of mCLEC9A on CD8α+ DCs [190, 191] and its 
endocytic ability suggest that CLEC9A could be used for antigen targeting to DCs. 
Recently it was shown that antigens covalently coupled to anti-mouse CLEC9A are 
selectively cross-presented by CD8α+ DCs in vivo and when given along with an 
adjuvant, it induced potent cytotoxic T-lymphocyte (CTL) responses [191]. These CTL 











tumor eradication [191]. The results indicate that CLEC9A could be exploited for CTL 
cross-priming and tumor therapy.  
 
hCLEC9A could also induce particle uptake in macrophages, but not when expressed in 
fibroblasts. By definition a phagocytic receptor is able to confer phagocytic activity to 
normally non-phagocytic cell lines [47, 51, 217, 218]. Therefore, it was concluded that 
CLEC9A is not directly able to mediate particle uptake. The phagocytosis of zymosan 
particles can involve several macrophage receptors including Dectin-1 [102], FcγRs 
[218] and the human MR [47, 217]. In addition, residual low levels of endogenous 
Dectin-1 is expressed on RAW264.7 macrophages, which could be contributing to the 
phagocytosis process [51]. Dectin-1 also mediates particle uptake through a novel 
undefined mechanism, which requires additional tyrosine-proximal residues [106], these 
residues are absent in hCLEC9A. 
 
Despite the lack of an hCLEC9A ligand, it was still possible to further investigate the 
function of the signaling motif in the cytoplasmic tail of hCLEC9A using the chimeric 
receptor. Analysis of the predicted hCLEC9A polypeptide sequence (see section 3.1) 
predicted that the cytoplasmic tail contains an ITAM-like motif. The results demonstrate 
for the first time that hCLEC9A is an activation receptor, capable of triggering 
intracellular signaling via Syk kinase. This interaction is mediated by the cytoplasmic tail 
of hCLEC9A that contains a single tyrosine-based (YxxL) sequence, which can be 
considered to be an ‘ITAM-like’ motif [51]. These sequence motifs were first identified 











[120], and CLEC-2 [125]. The mechanism of Syk signaling via these motifs is unknown 
though it does require both SH2 domains of this kinase [124]. ITAM-like mediated 
signaling through Syk has largely been studied in myeloid cells with Dectin-1. Signaling 
via Syk occurs through a novel pathway involving CARD9 [127], and can induce a 
variety of cytokines (such as TNF, IL-6, IL-10, IL-23 and IL-2), the respiratory burst and 
the production of arachidonic acid [103, 219]. As hCLEC9A can signal via this pathway, 
there is a possibility that this receptor may be able to mediate some of these responses in 
DCs. 
 
Subsequently, it was also shown that none of the anti-CLEC9A antibodies are able to 
promote DC activation in vitro or in vivo as measured by the upregulation of co-
stimulatory molecules or induction of cytokines [190, 191]. Furthermore, treatment with 
anti-CLEC9A mAbs does not alter the response of DCs to poly I:C or CD40 ligation, 
suggesting that anti-CLEC9A mAbs do not provoke signaling through the receptor, at 
least in a soluble form [191]. Antibodies to Dectin-1, similarly do not act as agonists for 
its receptor, the reason for this may be that the antibodies do not elicit the degree of 
cross-linking required to achieve productive signaling [103].  
 
All the results put together suggest that CLEC9A mediate the uptake of antibodies and 
promote antigen cross-presentation in a restricted subset of DCs, and the activatory 
potential of this receptor could potentially lead to various downstream signaling events 
that could initiate inflammatory responses that play a key role in tumor rejection or for 












Ligand screen for mCLEC9A 
6.1 Introduction 
Since the release of the human and mouse genome sequences, many novel ligand-orphan 
cell surface receptors have been identified. As indicated by sequence analyses, CLEC9A 
is most homologous to the “Dectin-1 cluster” receptors. Dectin-1, LOX-1 and CLEC-2 
have been reported to bind a diverse, unrelated range of endogenous and exogenous 
ligands, whilst CLEC-1, CLEC12B and MICL have no published ligands. It is therefore 
not clear what a ligand for CLEC9A might be based on its shared homology to related 
molecules. 
 
Given the limitation in obtaining primary hCLE 9A+ cells for analysis and the difficulty 
obtaining ethical approval for human tissues for ligand screening, I resorted to focusing 
on the murine orthologue to continue elucidating the physiological role of the receptor in 
the immune system. This chapter describes my investigation into the identifying possible 




6.2.1 Ligand screen of mCLEC9A using reporter cells 
The first approach involved expressing mCLEC9A in a reporter cell line. This approach 
employs BWZ.36 cells containing a β-gal reporter construct that is activated via NFAT, 











CTLRs [73, 175]. BWZ.36 cells were retrovirally transduced to express a chimeric 
mCLEC9A/CD3ξ receptor and in these reporter cells, ligand binding to the mCLEC9A 
CTLD induces signaling through the CD3ξ cytoplasmic tail as well as the induction of 
IL-2 and β-galactosidase (Figure 6.1 A). As a mAb against mCLEC9A was not available, 
the surface expression of the mCLEC9A transfectants cells was detected by using a 
purified polyclonal antibody raised in rats against mCLEC9A. Serum collected prior to 
the immunization of rats was used as a negative control, referred to as pre-bleed. The cell 
surface expression of this construct as well as a control chimera of mDectin-1/CD3ξ was 
confirmed by flow cytometry (Figure 6.1 B).  
 
Single cell suspensions isolated from various mouse tissues were co-cultured with the 
reporter cells overnight at 37°C. After the overnight incubation period the supernatants 
were collected and tested for the production of IL-2 by ELISA (Figure 6.1 C). By 
comparison with the Dectin-1 reporter cells, which were used as a control, significant 
induction of IL-2 was observed in the lung, heart, brain, kidney and bone marrow and to 
a lesser degree in spleen and liver. Similar results were obtained by the β-galactosidase 
staining (Figure 6.2), which indicating that the induction of IL-2 was not induced by the 
tissues themselves but from a specific endogenous ligand express on these cells (shown 
in Figure 6.1 C).  These data therefore suggest that mCLEC9A recognizes an endogenous 





































Fig. 6.1 mCLEC9A recognises an endogenous ligand. A) Cartoon representation of the 
CLEC9A/CD3ζ chimeric receptor and signal transduction pathway in BWZ.36 reporter cells. 
B) Flow cytometry of BWZ.36 cells stably expressing mCLEC9A or mDectin-1/ CD3ζ chimeric 
receptors stained with anti-mCLEC9A polyclonal antibody and anti-mDectin mAb (2A11). The 
filled histograms indicate isotype controls. C) IL-2 production from BWZ.36 reporter cells after 
co-culture with single cell suspensions isolated from various murine organs, as indicated. 
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Fig. 6.2 X-gal staining of reporter cells. BWZ.36 reporter cells expressing mCLEC9A 
(upper panel) and Dectin-1 (lower panel) were stimulated with single cell suspensions 











We next used cellular suspensions at various concentrations to test for the production of 
the IL-2 over time at 3, 6 and 20 hours of incubation at 37°C (Figure 6.3). The optimal 
time point for IL-2 production was after 20 hours of incubation at 37°C using 1x106 cells 
from each mouse tissue. The results obtained in the optimization of IL-2 induction 
(Figure 6.3) were similar to the results shown in Figure 6.1 C and 6.2. The lung, bone 
marrow, kidney, heart, spleen and brain once again tested positive for the induction of IL-
2, while the liver and thymus did not induce significant levels of IL-2.  
 
6.2.2 Screening tissues with an Fc-mCLEC9A soluble protein 
An alternative method was used to probe cells isolated from numerous mouse tissues by 
flow cytometry, using a soluble Fc-mCLEC9A fusion, similar to the human Fc-CLEC9A 
protein described in chapter 4. Using this approach, we could detect limited binding of 
Fc-CLEC9A to cells isolated from brain, kidney and lung (Figure 6.4). This interaction 
appeared to be specific, as similar binding was not obtained with Fc-CLEC12B, which 
was used as a control. These results confirmed the result obtained from the IL-2 and β-
galactosidase assay, however, there was no binding of Fc-mCLEC9A to liver, thymus, 
bone marrow, heart and spleen detected by flow cytometry.  
 
6.2.3  Immunohistochemistry of tissues stained with Fc-mCLEC9A 
Various mouse organs were collected and sectioned as described in Material as Methods. 
These tissues sections were stained with Fc-mCLEC9A as well as Fc-mCLEC12, which 
was included as a control. The binding of Fc-proteins was detected using anti-human Cy3 






































































































































































Fig. 6.3 Cellular titration of various mouse tissues and different time points for IL-2 
production. IL-2 production from BWZ.36 reporter cells after co-culture with single cells 
suspensions, at different concentrations as indicated, of various mouse tissues over time 
(3hrs, 6hrs and 20hrs). 
5x103 1x104 5x104 1x105 1x106 5x103 1x104 5x104 1x105 1x106
5x103 1x104 5x104 1x105 1x106
5x103 1x104 5x104 1x105 1x106 5x103 1x104 5x104 1x105 1x106
5x103 1x104 5x104 1x105 1x106
5x103 1x104 5x104 1x105 1x106






















































































Fig. 6.4 mCLEC9A recognises an endogenous ligand. Flow cytometric 
analysis of live single cell suspensions isolated from various murine tissues, as 
indicated, and stained with Fc-mCLEC9A (dotted grey line) and Fc-CLEC12B 
(solid black line) was included as a control. The data are representative of three 
independent experiments. 
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Figure 6.5 Immunohistochemistry of various mouse organs stained with Fc-
CLEC9A. Various tissues were stained with either Fc-mCLEC9A or mCLEC12B. Staining 











Unfortunately the staining of these tissue sections with the Fc-proteins was nonspecific. I 
attempted to optimize the fixation method of the tissues, but was unable to get rid of the 
nonspecific binding.  
 
6.2.4  Screening various heat-killed pathogens as possible exogenous ligands 
The mCLEC9A/CD3ξ reporter cells were also used to screen for any exogenous 
ligand(s). The reporter cells were co-cultured with various heat-killed pathogens, 
including E. coli, Pneumocystis, M. Tuberculosis, H.influenzae, S. aureus, zymosan and 
N. meningitidis. After the 20-hour incubation period at 37°C the supernatants were 
collected and tested for the production of IL-2 by ELISA. There was no induction of IL-2 
detected for any of the microbial ligands tested as shown in Figure 6.6, suggesting that 
the receptor does not function as a PRR. Dectin-1 was included as a control and showed 
increased IL-2 production upon zymosan binding, as expected [29]. Unstimulated cells 
were also included as a negative control. The β-galactosidase staining was used to verify 
the IL-2 results and confirmed that mCLEC9A did not recognize any of the pathogens 
tested (data not shown). 
 
6.2.5 Screening soluble Fc-proteins as possible ligands 
Recently AICL (CLEC12B), an activating CTLR expressed on myeloid cells [230], was 
identified as a ligand for NKp80, which is a NK cell-specific stimulatory receptor [231, 
232]. NKp80 and AICL are both NKC-encoded receptors, the NKp80-AICL interactions 


























































Fig. 6.6 mCLEC9A does not recognise an exogenous ligand. IL-2 production 
from BWZ.36 reporter cells after co-culture with various heat killed pathogens (CM: 
culture medium; Bio: E.coli bio particles; K1: E.coli; DH5a: E.coli; Pneu: 
Pneumocystis; M.TB: Killed M. Tuberculosis; EAC: H.influenzae; RD: H.influenzae; 
S.a: S.aureus; Zy: zymosan; Men: N.meningitidis; as indicated. Dectin-1 (black) was 

















potentially influence the initiation and maintenance of immune responses [230]. 
Previously, Nkrp1d, which is a NK cell receptor was shown to recognize the specific C-
type lectin-related ligand Clrb, which is expressed on DCs and macrophages [73]. These 
receptor-ligand pairs are co-localized in the centromeric end of the NKC, and their gene 
order is in opposite transcriptional orientation [73]. Therefore, it might be possible that 
CLEC9A might be genetically linked to a C-type lectin-related ligand in the ‘Dectin-1 
cluster’. Since the main focus of our laboratory is to functionally characterize CTLRs that 
are part of the ‘Dectin-1 cluster’, we had the advantage of having all the protein 
constructs and soluble Fc-proteins for Dectin-1, CLEC-1, CLEC-2, MICL and CLEC12B 
available to use for screening as possible ligands for CLEC9A. To explore this, the 
reporter cells (BWZ.36 mCLEC9A/ mCD3ζ) were incubated with the soluble Fc-proteins 
at 4°C and binding was detected by anti-Fc flow cytometry (Figure 6.7). All of these Fc-
proteins tested negative. Therefore the results indicate that mCLEC9A does not recognize 
any of these specific CTLRs as an endogenous ligand. 
 
6.3 Discussion 
This chapter describes the identification of possible endogenous and exogenous ligand(s) 
for mCLEC9A. Various approached were attempted in order to find ligands for 
mCLEC9A, this involved the screening of a variety of mouse tissues and heat-killed 
pathogens. The specific ligand for mCLEC9A was not identified, however, some results 
did indicate that mCLEC9A recognized an endogenous ligand(s) in brain, kidney and 
lung. This was confirmed by using two approaches, the reporter cell system and anti-Fc-







































Fig. 6.7 BWZ.36-mCD3ζ/mCLEC9A transduced cells stained with various soluble 
Fc-proteins. The transduced BWZ.36 cell line was stained with mCLEC9A, Dectin-1, 
CLEC-2, CLEC12B, MICL and CLEC-1 to look for possible ligands. All the Fc-proteins 




















future identification of specific endogenous mCLEC9A ligand(s). Using methods to 
increase activity of binding such as those used to demonstrate the presence of a cell 
surface ligand for EMR3 on macrophages and neutrophils [233], could be used for future 
studies to enhance ligand detection. In our hands we could not detect any microbial 
ligands for mCLEC9A, suggesting that this receptor is unlikely to function as a PRR.  
 
It is known that the ligands of the ‘Dectin-1 cluster’ are structurally unrelated. Dectin-1 
binds β-glucans as well as an unknown endogenous T cell antigen [29, 39]; LOX-1 
recognizes aged cells, bacteria, activated platelets and Ox-LDL [52, 87], whilst CLEC-2 
binds to the endogenous ligand podoplanin [77] as well as the snake venom toxin 
rhodocytin which elicits a powerful platelet activation response [101]. There is also some 
evidence for an endogenous ligand for mMICL [175]. Therefore, we could not predict 
what the ligand for CLEC9A might be by comparing the receptor homology with 
receptors of known ligands. It is even possible that CLEC9A could bind other C-type 
lectins that are not part of the ‘Dectin-1 cluster’ 
 
The reporter cells were very useful for identifying which organs might be used for future 
ligand searches, although this approach does not give any detail as to the specific 
endogenous ligand recognized by mCLEC9A. A future approach could utilize flow 
cytometric cell sorting to isolate the cells that bind Fc-mCLEC9A. Once the positive 
populations of Fc-binding cells are obtained, these cells could either be stained with 
various specific cell markers to identify the cellular population that express the 











identified these cells could be sorted and cell lysates generated from them and analyzed 
by immunoprecipitations assays using anti-FcCLEC9A as a probe, and various proteomic 
approaches, including mass spectrometry, could be used to define the specific 
endogenous ligand for mCLEC9A.   
 
Some activatory CTLRs bind exogenous ligands, however I could not detect any binding 
of mCLEC9A to the microbes used for in these experiments. It may be that fixation of the 
pathogens tested, damaged the ligand for mCLEC9A, so live microbes might be used for 
future experiments. Since CLEC9A also shares high homology to LOX-1, a potential 
ligand(s) that could be tested using the same approach are apoptotic/aged cells, activated 
platelets and heat shock proteins (Hsps), which have all been reported as ligands of LOX-
1. Another possibility is that CLEC9A functions as part of a complex, which could be a 
problem if using the above mentioned screening approach, because the reporter cells 
expressing mCLEC9A is an artificial system that might lack the molecules needed for 
binding its natural ligand(s). In such an event, primary cells expressing mCLEC9A, such 
as CD8α+ DCs, would need to be assayed for the identification of a CLEC9A-dependent 
interaction with ligand-expressing cells. 
 
DCs utilize several pathways in antigen capture such as macropinocytosis; receptor-
mediated endocytosis via CTLRs (including MMR and DEC-205) or Fcγ receptors 
(CD64 and CD32) for the uptake of opsonized particles; and phagocytosis of particles 
such as apoptotic and necrotic cell fragments (involving CD36 and integrins), viruses and 











internalize the peptide loaded Hsps g96 and Hsp70 through unknown mechanisms [234]. 
The endocytic ability and restricted expression of CLEC9A on CD8α+DCs suggest that 
this receptor could mediate antigen capture of dying cells [207, 224, 225] for antigen 
processing and presentation [224]. This observation could be exploited in future studies 




























7.1    Review of aims of the project 
The aim of this thesis was to characterize a novel group V C-type lectin-like receptor, 
CLEC9A, which is part of the ‘Dectin-1 cluster’ [171]. In this chapter I will discuss my 
results obtained from my characterization of the receptor’s polypeptide sequence, its 
mRNA and protein expression, its signaling abilities, and its ligand(s) to ultimately 
elucidate the role that this receptor plays in the immune system.  
 
7.2   Summary of key findings 
 
7.2.1 CLEC9A is a novel human CTLR with an ITAM-like motif 
The sequence analysis of CLEC9A indicates that it is part of the ‘Dectin-1 cluster’ of 
receptors that belong to the group V CTLRs. CLEC9A lacks the calcium coordinating 
amino acid residues found in the classical C-type lectins [8]. The stalk region of 
hCLEC9A contains two cysteine residues that are potentially involved in receptor 
dimerization, and a single predicted N-linked glycosylation site. The cytoplasmic tail of 
CLEC9A contains a single tyrosine residue within a sequence showing similarity to the 
ITAM-like sequence of Dectin-1 [51], indicating that CLEC9A may act as an activatory 
receptor. The hCLEC9A gene consists of six exons and is located on the plus strand of 












Sequence analysis shows that the protein encoded by murine clec9A is 53% identical to 
human clec9A, retains most of the structural features described above, including the 
intracellular signaling motif. However, the murine receptor appears to lack N-
glycosylation sites as well as one of the cysteine residues in the stalk region. Similar to 
the human gene, mCLEC9A is located on the plus strand of chromosome 6 and also 
includes a variety of alternatively spliced transcripts. The protein sequence of CLEC9A is 
most homologous to Dectin-1 and MICL. Subsequently two independent publications 
appeared, which also identified CLEC9A as a novel CTLRs. Sancho et al. [191] and 
Caminschi et al. [190] published similar findings, however they characterized a seven 
exon transcript of mCLEC9A in both their studies. This transcript contains an ‘extra’ 
exon in the CTLD of mCLEC9A and encoding a protein of 264 amino acids. All the 
‘Dectin-1 cluster’ receptors consist of six exons, therefore I decided to characterize the 
six exon transcript encoding a protein of 238 amino acids. 
 
7.2.2 hCLEC9A is predominantly expressed as a single transcript on blood DC 
and a subset of monocytes 
At the mRNA level, hCLEC9A is expressed in most tissues but predominantly in brain, 
thymus and spleen with no apparent splice variants. The high level of hCLEC9A 
expression in the thymus and spleen, may suggest a role in immunity. Multiple transcripts 
of mCLEC9A were detected in spleen, lung and day 11 embryo, however in most other 
tissues mCLEC9A appears to be expressed as a single transcript.  We used a mAb 
generated against hCLEC9A to further characterize the expression of hCLEC9A in 











peripheral blood leukocytes. The receptor is predominantly expressed by BDCA-3+ DCs, 
which represent less than 0.05% of PBMCs [197]. The surface expression of hCLEC9A 
on BDCA-3+ DCs was confirmed by Sancho et al. [191] and Caminschi et al. [190]. 
hCLEC9A is also expressed on small subsets of CD14+CD16- monocytes and on 
CD64+CD11b+CD14- cells, which we were unable to identify further. I did not 
characterize the expression of mCLEC9A on primary cells, but Sancho et al. [191] and 
Caminschi et al. [190] showed that mCLEC9A is expressed on CD8α+ DCs and at much 
lower levels on pDCs. 
 
7.2.3   hCLEC9A protein is expressed at the cell surface as a dimer and is N-
glycosylated 
hCLEC9A is expressed at the cell surface, similar to the other receptors in the “Dectin-1 
cluster”, suggesting that hCLEC9A does not require an adaptor molecule for expression. 
The hCLEC9A receptor is highly N-glycosylated similar to MICL, but bears no O-
glycosylation. Like most group V CTLRs, hCLEC9A appears to be expressed as a dimer. 
In contrast, mCLEC9A was detected as a monomer that bears no N-/O- glycosylation, but 
is similarly expressed at the cell surface of transfected cells. Sancho et al. [191] reported 
that their seven exon molecule exists as a dimer and predicted it to be glycosylated.  
 
7.2.4 hCLEC9A can associate and signal via Syk kinase and is able to transmit 
activatory signals via its ITAM 
hCLEC9A functions as an activation receptor capable of triggering intracellular signaling 
via Syk kinase. This interaction was mediated by the cytoplasmic tail, which possesses a 











motif” [124]. These conserved sequences were identified in two other receptors of the 
“Dectin-1 cluster”, Dectin-1 itself [51], and more recently CLEC-2 [101]. The 
mechanism of Syk signaling via these receptors is still unknown, both SH2 domains of 
this kinase are required, and may occur through the bridging of two receptor chains. 
 
7.2.5 hCLEC9A is an endocytic receptor 
Cross-linking hCLEC9A on the surface of transduced cells, using anti-CLEC9A mAb, 
led to the rapid reduction of the receptor at the cell surface, indicating that the receptor 
was mediating internalization of the bound antibodies. The results show that hCLEC9A 
function as an endocytic receptor. The endocytic ability of human and murine CLEC9A 
was confirmed by Sancho et al. [191], primary cells and transduced cell lines were used 
in their experiments. This indicate that CLEC9A may be useful for targeting antigens to 
mouse CD8α+ DCs or their human equivalent BDCA-3+ DCs 
 
7.2.6 hCLEC9A is not a true phagocytic receptor 
Since the ligand for hCLEC9A is still unknown, I utilized a chimeric receptor, which 
could bind zymosan to study the phagocytic ability of this receptor. Although we could 
demonstrate that hCLEC9A could induce particle uptake in macrophages, the receptor 
was unable to confer phagocytic activity in normally non-phagocytic cell lines, therefore 
it was concluded that CLEC9A is not directly able to mediate particle uptake. However, 
the assay used was based on using unphysiological cell types in an artificial system and 
have various limitations. Once the ligand for hCLEC9A is known physiological cells 











expressed on DCs and may therefore require the assistance of DC-specific signaling 
molecules to direct phagocytosis. 
 
7.3 Future directions  
 
7.3.1 True physiological function 
DCs consist of multiple subsets with specialized functions [235], contributing to the 
maintenance of self tolerance and the induction of adaptive immunity [215]. There is a 
definite need to identify specific surface molecules on DCs, so to manipulate distinct DCs 
subsets and to regulate the immune responses. This thesis describes the characterization 
of a novel CTLR, CLEC9A, which is restricted to human BDCA-3+ DCs with the ability 
to mediate endocytosis. Subsequently, it was shown that mCLEC9A is also selectively 
expressed on mouse CD8α+ cDCs (proposed to be the equivalent of human BDCA-3+ 
DCs) and pDCs [190, 191].  
 
The conventional DCs can be distinguished as “inflammatory” DCs, which develop from 
monocytes upon inflammation [236]. These cDCs have been divided into those 
expressing CD8α+ (CD8α+ cDCs) and those that do not (CD8α- cDCs). They also differ in 
functions, where the CD8α+ DCs are specialized for cross-presentation of exogenous 
antigens on MHC class I [205, 237, 238] as well as being major producers of IL-2 upon 
activation [226, 227]. Despite all the functional differences known for mouse cDCs 
subsets, there has been little information on the translation of this knowledge to the 











subtype of myeloid DCs [196, 202, 239] and share similarities with mouse CD8α+ DCs, 
including high levels of TLR3 mRNA, absence of TLR7 transcripts and expression of 
nectin-like protein 2 (Necl-2) [204]. BDCA-3+ DCs may be the potential human 
equivalent of mouse CD8α+ DCs. Therefore, the highly restricted expression of CLEC9A 
on these DCs subsets will be useful for future studies to determine whether the human 
CLEC9A+ BDCA-3+DCs have the same functions as the mouse CLEC9A+ CD8α+ DCs. 
 
TLRs mainly induce DC maturation, whereas the CTLRs might act as constituents of the 
powerful antigen capture and uptake mechanism of DCs [33]. Several C-type lectins have 
the ability to endocytose a broad array of foreign material that gets targeted into 
lysosomal and MHC class II+ late endosomes to mediate presentation to T cells, including 
MR, DEC-205, DC-SIGN, Dectin-1, CLEC-1 and BDCA-2 [41-43]. Specific mAbs can 
be used to target antigens to particular DCs surface molecules that modulate immune 
responses [192, 210, 214, 222]. CLEC9A is largely restricted to DCs and was used as a 
target for the delivery of antigens to DCs [190]. mCLEC9A expressed on DCs was 
targeted with a single injection of anti-mCLEC9A mAb that gave an marked increased 
mouse response to rat Ig, as well as the enhancement of responses to ovalbumin when 
conjugated to anti-mCLEC9A mAb [190]. This is a promising feature of CLEC9A if the 
ultimate aim is to improve antibody responses to vaccines. 
 
Furthermore, the requirements for enhancing Ab responses by targeting mCLEC9A 
require that no additional DCs activation agents or adjuvants were employed. Therefore, 











conditions to confirm that the enhanced Ab response was not due to traces of endotoxin 
or other microbial products, the experiments were repeated using MyD88-/-TRIF-/- mice, 
which are unable to respond to TLR ligands [240, 241]. This indicates that the response 
was independent of ‘danger’ signals mediated by TLR ligands [190].  
 
An equally important feature of CLEC9A are its endocytic properties suggest that it 
might be a useful receptor for targeting antigens specifically to mouse CD8α+ or human 
BDCA-3+ DCs. Recently published results show that in vivo delivery of modified 
ovalbumin peptide covalently coupled to anti-mCLEC9A mAb resulted in the selective 
delivery of antigen for MHC class I cross-presentation by CD8α+ DCs [190, 191]. 
Indicating that immune responses elicited by anti-mCLEC9A targeting in vivo primarily 
reflect the antigen presenting activity of CD8α+ DCs. 
 
DCs have the ability to regulate adaptive immunity, which suggests that these cells could 
be used for clinical research through targeting antigens to DCs in vivo [214, 215]. The 
success for DC targeting depends on identifying a suitable DC-expressed cell surface 
receptor that mediates endocytosis. Based on these specifications Sancho et al. [191] 
assessed the potential of mCLEC9A targeting to induce CTL responses and tumor 
immunotheraphy. For this experiment they tested conjugates of antigen and anti-
CLEC9A mAb under the cover of anti-CD40, which provides extra signals for 
immunogenicity [192, 210]. The results obtained were comparable to those obtained with 
DEC-205 where small amounts of targeted antigen similarly induce potent CTL 











applied this protocol to a tumor model, choosing B16 melanoma. Their results show that 
targeting antigens to mCLEC9A can eradicate tumors. These results suggest that 
targeting antigens to mCLEC9A could be exploited as an immunotherapeutic strategy for 
cancer.  
 
These results conclude that CLEC9A is a novel activating CTLR expressed on BDCA-3+ 
DCs and is conserved between species. Together with the findings of Sancho et al. [191] 
and Caminshi et al. [190]  our results could help to translate the information on mouse 
DC biology to human clinical studies. CLEC9A has the potential to be used as a target 
for enhancing the effectiveness of vaccines as well as improving both antibody and T cell 
responses to antigens. However, future studies will be needed to determine whether 
CLEC9A targeting induces cross-tolerance and whether CLEC9A may therefore be a 
promising target for promoting immunological unresponsiveness.  
 
7.3.2  Possible ligand(s) for CLEC9A 
To elucidate the true function of CLEC9A the identification of a ligand is crucial. Since I 
found a possible lead for an endogenous ligand by using the reporter cell method, future 
studies could continue using this technique as well as utilizing anti-Fc based flow 
cytometric assays.  
 
Based on the restricted DC expression and endocytic function of CLEC9A, I predict that 
heat shock proteins (Hsps) are strong candidates to be the potential endogenous ligand(s) 











regulation [242, 243]. The presence of mammalian Hsps in the extracellular environment 
is an indication of intracellular trauma (e.g. cell death), while the detection of pathogen-
derived Hsps indicates the onset of local infection [234]. Cells have the ability to sense 
these Hsps as molecular chaperone-based ‘alarm’ signals, therefore the existence of Hsp 
receptors has been postulated. Studies have shown that Hsps are complex ligands, once 
these molecules are released from the cell they often carry intracellular derived 
polypeptides, indicating that their receptors may recognize Hsp itself, its cargo or the 
Hsp-peptide complex (Hsp.PC) [244, 245]. The antigenic peptides carried by Hsp70 and 
gp96 (which are different classes of Hsps) stimulate a specific T cell response to the cells 
of the peptide origin, through antigen cross-presentation [246, 247]. Thus the specific 
peptide cargo of Hsps is important for different immune responses.  
 
Hsp70 have various functions in the immune system for instance, it can bind peptide 
antigens, transport them to APCs and can direct antigens towards MHC class I molecules 
[244, 248]. Additionally Hsp70 is a potent inflammatory stimulator that triggers the 
innate immune system and break tolerance to tumor antigens [242]. The properties of 
many Hsps are transmitted through cell surface molecules and the study of Hsp receptors 
is still incomplete, although some important findings have been made by screening 
candidate hsp70 receptors. A previous study showed that Hsps70 binds readily to SCER-
1 and FEEL-1 as well as LOX-1, which are all Scavenger receptors (SR). Each of these 
receptors can mediate Hsp70 internalization [249, 250]. LOX-1 plays an important role in 












Several group V CTLRs sharing structural homology with LOX-1, including Dectin-1, 
NKG2D and CD94 [14] were tested for binding to Hsp70 [234], suggesting that the 
CTLD of these receptors consists of a conserved ligand interaction domain responsible 
for the recognition of Hsp70. Dectin-1 showed no significant Hsp70 binding, however 
NKG2D showed a significant affinity for Hsp70 [234]. These findings suggest that a 
number of CTLRs can serve as receptors for Hsp70, although the CTLD was not the sole 
determinant required for Hsp70 interaction [234].  
 
In summary Hsps can transport antigens across the plasma membrane of APCs as cargo 
and deliver the antigens to the MHC class I receptors [251], leading to the activation of 
APC and stimulation of cytotoxic T lymphocytes [247]. Since CLEC9A is expressed on 
blood DC, is able to mediate endocytosis and since it can be exploited for CTL cross-
priming and tumor therapy, Hsps are potential candidates to be screened as potential 
ligands for CLEC9A. 
 
In conclusion, CLEC9A is a promising receptor that could be used as a novel DCs 
marker, could help translate the information on mouse DCs biology to human clinical 
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